Prevalence, correlates, effects and detection of left ventricular systolic dysfunction in an urban population by McDonagh, Theresa A.
THE PREVALENCE, CORRELATES, EFFECTS AND 
DETECTION OF LEFT VENTRICULAR SYSTOLIC 
DYSFUNCTION IN AN URBAN POPULATION 
THERESA A McDONAGH 
Submitted for the degree of Doctor of Medicine 







FORMAL DECLARATION 12 
CHAPTER 1: General Introduction 13 
1.1 Chronic Heart Failure and Left Ventricular Systolic Dysfunction 14 
1.1.1 The Syndrome of Heart Failure 14 
1.1.2 Chronic Heart Failure 14 
1.1.3 Definition of Chronic Heart Failure 15 
1.1.4 Cardiac Dysfunction 15 
1.1.5 Left Ventricular Dysfunction: Systolic and Diastolic 16 
1.1.6 Left Ventricular Systolic Dysfunction 17 
1.1.7 From Asymptomatic Left Ventricular Systolic 17 
Dysfunction to Chronic Heart Failure 
1.1.8 Multisystem Dysfunction 18 
1.1.9 Updated Definition Of Chronic Heart Failure 20 
1.2 The Epidemiology of Chronic Heart Failure 20 
1.2.1 Prevalence of Chronic Heart Failure 21 
1.2.2 Prevalence of Left Ventricular Systolic 22 
Dysfunction 
1.2.3 Prevalence of Diastolic Dysfunction 24 
2 
1.2.4 Chronic Heart Failure and Left Ventricular Systolic 24 
Dysfunction in High Risk Populations 
1.2.5 Incidence of Chronic Heart Failure 25 
1.2.6 Aetiology of Chronic Heart Failure and Left Ventricular 25 
Systolic Dysfunction 
1.2.7 Importance of Chronic Heart Failure and Left Ventricular 29 
Dysfunction 
1.2.8 Trends in the Epidemiology of Chronic Heart Failure 32 
1.3 Exercise Testing in Chronic Heart Failure 33 
1.3.1 Oxygen Uptake and Left Ventricular Dysfunction 33 
1.3.2 Relationship Between Measures of Effort Capacity 34 
and Other Markers of Chronic Heart Failure 
1.3.3 Role in Assessment of the Aetiology of Left Ventricular 37 
Systolic Dysfunction 
1.3.4 Role in Prediction of Prognosis 37 
1.4 The Natriuretic Peptides 38 
1.4.1 Production 39 
1.4.2 Exertion of Actions 39 
1.4.3 Clearance 40 
1.4.4 Actions 40 
1.4.5 Pathophysiology 41 
1.4.6 Diagnosis in Patient Groups 42 
1.4.7. Prognosis 43 
1.4.8 Monitoring of Treatment 43 
3 
1.4.9 Therapeutic Modulation 44 
1.5 The Angiotensin Converting Enzyme Insertion /Deletion Polymorphism 
45 
1.5.1 Myocardial Infarction 46 
1.5.2 Hypertension 47 
1.5.3 Cardiac Failure 47 
1.6 Aims of the Thesis 48 
CHAPTER 2: Methods 50 
2.1 Population 51 
2.2 Echocardiogram 53 
2.3 Interview and Questionnaire 57 
2.4 Blood Pressure 58 
2.5 Body Mass Index 58 
2.6 Venous Blood Sampling 58 
2.7 12 Lead Electrocardiogram 61 
2.8 Alcohol Consumption 61 
2.9 Exercise Test 61 
2.10 Ethics 63 
CHAPTER 3: The Prevalence of Symptomatic and Asymptomatic 64 
Systolic Dysfunction in an Urban Population 
3.1 Introduction 65 
3.2 Methods 66 
4 
3.3 Results 68 
3.4 Discussion 78 
CHAPTER 4: The Correlates of Left Ventricular Systolic 85 
Dysfunction in an Urban Population 
4.1 Introduction 86 
4.2 Methods 86 
4.3 Results 88 
4.4 Discussion 97 
CHAPTER 5: The Effect of Left Ventricular Systolic Dysfunction 101 
on Effort Capacity in an Urban Population 
5.1 Introduction 102 
5.2 Methods 102 
5.3 Results 103 
5.4 Discussion 112 
CHAPTER 6: Biochemical Detection of Left Ventricular Systolic 115 
Dysfunction in an Urban Population 
6.1 Introduction 116 
6.2 Methods 117 
6.3 Results 118 
6.4 Discussion 131 
5 
CHAPTER 7: The Effect of the Angiotensin Converting Enzyme 
Insertion /Deletion Polymorphism on Left Ventricular Systolic 
Dysfunction in an Urban Population 138 
7.1 Introduction 139 
7.2 Methods 140 
7.3 Results 140 
7.4 Discussion 153 





The work presented in this thesis was carried out in Professor HJ Dargie's 
Research Unit in the Department of Cardiology at the Western Infirmary, 
Glasgow. It was funded, chiefly, by a grant from the Scottish Office Home 
and Health Department. I have drawn upon the skills of many, I cannot 
mention them all, but I wish to cite those who have been most involved. 
As it was a collaboration with the Scottish MONICA Project, I wish to thank Dr 
Caroline Morrison for her tireless efforts in making the MONICA Population 
available for screening again and her endeavours to ensure an optimal 
response rate. I would also like to acknowledge her kindness to me 
personally during the painstaking hours of echo analysis. The expert skills of 
others at the MONICA project were also invaluable: Wilma Leslie, Aileen Urie 
and Mary Mitchell for the exercise test coding. 
The help of my "screening team" has left an enormous impression on me. 
The echocardiograms were in the main carried out by Esther Rooney, to 
whom I am much indebted. I wish to thank Susan Davison for her expertise 
in performing and coding the exercise tests and Wendy Linden for "manning" 
the nursing station. 
The natriuretic peptide measurements were performed in the lab of Dr Ian 
Morton and funded by Merck Sharpe and Dohme. 
All the data collected in this study was entered at the Robertson Centre for 
Biostatistics at the University of Glasgow. I wish to thank Audrey Lawrence 
7 
for her assistance in data management and Professor Ian Ford for his 
statistical advice. 
I also wish to extend by gratitude to Francois Cambien and his staff at French 
Inserm for carrying out the ACE genotyping and also to Sandy Cook at the 
RHSC for extracting the DNA. 
I must also acknowledge all the randomly sampled subjects from North 
Glasgow who attended the study and endured the rigours of an 
echocardiogram, exercise test and blood sample with the characteristic far- 
sightedness and cheerfulness of Glaswegians. It my earnest hope that any 
use of this data for provision of health care in the future will be of benefit to 
them. 
I would like to express my thanks to my colleagues John Byrne and John 
McMurray for screening a session per week in the early stages of this project. 
I also acknowledge the help of John McMurray with some of the manuscripts 
which this work generated. I am grateful to Stephen Robb for undertaking my 
CRI committments while I analysed the echocardiograms. I am also indebted 
to Malcolm Metcalfe who critically read the first draft of this thesis. 
Very few people have the privilege of undertaking research in such an 
excellent environment as I did, which leaves me to thank Professor Henry 
Dargie for providing me with the opportunity. I also commend him for his 
interminable patience with me and for his inexhaustible optimism and 
enthusiasm, which has often kept me going. 
Above all I would like to thank my parents. This work, quite simply, would not 
have been possible without them. 
8 
ABSTRACT 
The prevalence of chronic heart failure (CHF) in most epidemiological studies 
has been determined by using clinical criteria. 
In this thesis, in contrast, left ventricular systolic function was assessed 
objectively by echocardiography in a cross -sectional survey of 2000 men and 
women aged 25 -74, randomly sampled from a geographical area. Left 
ventricular ejection fraction (LVEF) was measured using the Biplane 
Simpson's Rule Method. Its aims were to document the prevalence of both 
symptomatic and asymptomatic left ventricular systolic dysfunction; ascertain 
the correlates of left ventricular systolic dysfunction; assess its effects on 
effort capacity; determine the usefulness of the natriuretic peptides in 
detecting systolic dysfunction; and to explore the possibility of a genetic 
component to left ventricular systolic dysfunction by examining the 
relationship between left ventricular systolic dysfunction and the angiotensin- 
converting enzyme insertion /deletion polymorphism (ACE I /D). 
In the 1640 subjects who attended (83 %), the mean left ventricular ejection 
fraction was 47.3 %. The prevalence of `definite' left ventricular systolic 
dysfunction (a LVEF <_30 %) was 2.9 %: it was 0.7% in men aged 35 -44 years 
and 6.4% in men >65 years being also higher in men (4 %) than women (2 %). 
One point five percent (1.5 %) had symptomatic left ventricular systolic 
dysfunction and 1.4% asymptomatic left ventricular systolic dysfunction. 
In those with left ventricular systolic dysfunction, 83% had evidence of 
ischaemic heart disease (IHD), in contrast to 21% of those without left 
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ventricular systolic dysfunction (p <0.001). Hypertension was more common 
in those with an abnormal ejection fraction (60% compared to 22 %), p <0.001) 
but hypertension unaccompanied by IHD was not significantly more common 
in those with left ventricular systolic dysfunction. 
Left systolic ventricular dysfunction was associated with a significant 
reduction in exercise duration. In subjects in whom this was asymptomatic 
there was a trend towards decreased effort capacity. 
Plasma concentrations of the natriuretic peptides were significantly higher in 
those with left ventricular systolic dysfunction (the median concentration 
(interquartile range) of N -ANP was 2.8 [1.8,4.6] ng /ml and BNP; 24 [18,33] 
pg /ml) than in those without (N -ANP; 1.3[0.9,1.8] ng /ml and BNP; 
7.7pg/mI[3.4,13], p <0.001). The area under the Receiver Operator 
Characteristic Curves (SD) was greater using BNP; 0.88 (0.03) for all, 0.841 
(0.03) in those with IHD, 0.86(0.03) for subjects >_55 years and 0.84 (0.04) for 
those >_55 years with IHD. The same areas under the curve for N -ANP were 
0.75(0.05), 0.71(0.05), 0.72 (0.05) and 0.70 (0.06), respectively. A BNP 
concentration of . 17.9pg /ml gave a sensitivity of 77% (specificity 87 %) for 
detecting left ventricular systolic dysfunction in all subjects, improving to 92% 
(specificity 72 %) when the analysis was restricted to individuals >_ 55 with 
IHD. 
The DD genotype of the ACE I/D polymorphism was significantly more 
common in subjects with electrocardiographic evidence of myocardial 
infarction (MI) or major ischaemia. (Using II as a reference, the odds ratios 
normal versus major ischaemia or MI were: DD 1.53, ID 1.18:p =0.03 for 
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trend). In older patients ( >_51 yr.) with an ECG MI or major abnormality, LVEF 
was higher in those with the DD genotype (LVEF %: DD 44.6, ID 42.9, II 
40;p <0.02). LVEF was also greater in older patients with a systolic blood 
pressure (SBP) > than the median value (LVEF %: DD 47.5, ID 45.8, Il 44.6; 
p= 0.012). 
This work has shown that left ventricular systolic dysfunction is at least as 
twice as common than previous studies based on clinical criteria of CHF 
would suggest; about half is asymptomatic. Only 18% of subjects with 
definite left ventricular systolic dysfunction were taking an ACE inhibitor. Its 
main risk factors are IHD and hypertension in the presence of IHD; screening 
such high risk groups for left ventricular systolic dysfunction is worthy of 
consideration. Using a test such as BNP and targetting its use to individuals 
at high risk would lead to the identification of many more patients with left 
ventricular systolic dysfunction and, therefore, to the uptake of effective 
treatment. It would also lead to a more cost effective use of further 
investigation. 
This thesis also provides a mechanistic insight into the development of left 
ventricular systolic dysfunction by suggesting that while the DD genotype 
confers a higher risk of MI, it is associated with better preservation of LV 
function post MI, possibly by enabling more adequate compensatory 
hypertrophy. The ACE gene I/D polymorphism may, therefore, have a bi- 
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1.1 Chronic Heart Failure and Left Ventricular Systolic Dysfunction 
1.1.1 The Syndrome of Heart Failure 
Heart failure has been defined, in pathophysiological language, as a "state in 
which an abnormality of cardiac function is responsible for failure of the heart 
to pump blood at a rate commensurate with the requirements of the 
metabolising tissues or, to do so, only from an elevated filling pressure" 
(Braunwald, 1997). Whilst this is useful for the physiologist, the clinician 
requires a more pragmatic approach and it is at this point that problems with 
definition begin to emerge. 
The difficulty in defining heart failure, clinically, stems from the fact that heart 
failure is not a diagnosis, per se, but a clinical syndrome consisting of a 
constellation of symptoms and signs attributable, ultimately, to cardiac 
dysfunction. As such, it represents the final common pathway for most 
serious forms of heart disease (Lenfant, 1994). 
Contained within the above definition is a wide spectrum of 
pathophysiological states varying from those caused by rapid impairment of 
pump function eg. massive myocardial infarction, tachy or brady arrhythmias 
to the progressive and gradual impairment of myocardial function observed in 
a patient whose heart is subjected to pressure or volume overload for a 
prolonged period. 
1.1.2 Chronic Heart Failure 
This is the most common manifestation of heart failure and has largely 
replaced terms like "congestive cardiac failure ", "left heart failure ", "left 
ventricular failure" and "low output failure" as it describes more accurately the 
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persistent nature of the condition. Chronic heart failure (CHF) often follows 
an undulating course, being punctuated by episodes of decompensation. It 
occurs when one or more of several distinct pathologies which can also cause 
acute heart failure develop gradually or when the patient survives the initial 
insult and a number of adaptive mechanisms become operational allowing 
the patient to survive but with depressed cardiac function either at rest or on 
effort. 
1.1.3 Definition of Chronic Heart Failure 
Ideally, chronic heart failure should be diagnosed when a patient has: 
1 Symptoms of heart failure at rest or on effort, and 
2 Objective evidence of cardiac dysfunction at rest. 
A third element, that is, a response to treatment, with a diuretic, digoxin or 
angiotensin converting enzyme inhibitor, is also desirable, especially where 
the diagnosis is in doubt (Task Force on Heart Failure of the European 
Society of Cardiology, 1995). 
A simpler or more precise definition of chronic heart failure, currently, is 
unavailable as there is no cut -off value of cardiac dysfunction, be that a 
change in a parameter of contraction, thickening, flow, pressure, dimension or 
volume that can be used, reliably, to identify subjects with heart failure. The 
diagnosis relies on good clinical judgement based on the history, physical 
examination and appropriate investigations. 
1.1.4 Cardiac Dysfunction 
Thus, an essential element in the diagnosis of heart failure is the presence of 
cardiac dysfunction of which there are many types. Valvular, endocardial, 
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pericardial, myocardial pathologies and some extracardiac abnormalities, are 
all capable of producing the end stage condition of dyspnoea, fatigue and 
fluid retention. The relative importance of the different structural components 
of the heart as causes of heart failure varies geographically with the 
prevalence of the important types of heart disease i.e. ischaemic, 
hypertensive, rheumatic, valvular, infective, congenital and cardiomyopathic. 
1.1.5 Left Ventricular Dysfunction: Systolic and Diastolic 
By far the most common cause of chronic heart failure in industrialised 
societies is left ventricular dysfunction (LVD) due to myocardial disease and in 
particular, left ventricular systolic dysfunction. Here, pump failure occurs as a 
consequence of failure of contraction of the left ventricle (LV), most often as a 
result of myocyte loss secondary to myocardial infarction. 
Less commonly, chronic heart failure can result from failure of relaxation of 
the left ventricle leading to impaired filling. This diastolic dysfunction accounts 
for between 30 -40% of all chronic heart failure, and becomes increasingly 
prevalent with advancing age. It is also encountered more frequently in those 
with pre- existing systemic hypertension (Dougherty et al. 1984,Soufer et al. 
1985) as well as being the predominant variety of ventricular dysfunction in 
rarer conditions such as hypertrophic obstructive cardiomyopathy and 
amyloid. The natural history of diastolic dysfunction is not well studied. It is, 
however, thought to be associated with a better prognosis than systolic 
dysfunction (Nelson et al. 1975). 
The picture is further complicated in those with left ventricular dysfunction, 
due to IHD when both systolic and diastolic dysfunction frequently co- exist, 
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the former due to loss of myocardium and the latter due to one or more of 
replacement fibrosis, hypertrophy of non -infarcted myocardium and possibly, 
myocardial ischaemia. 
1.1.6 Left Ventricular Systolic Dysfunction 
In most cases, chronic heart failure is now thought to lie at the end stage of a 
progressive deterioration in left ventricular function, which can remain 
asymptomatic for years. In other words, when heart failure is diagnosed on 
symptoms and signs, the end stage of the disease is being detected - where it 
can have a mortality, untreated, of up to 50% per annum (Swedberg et al. 
1987). Thus, the full blown syndrome can be preceded by a long, latent 
phase, during which left ventricular damage is certainly present, but in which 
diagnosis on clinical grounds is impossible. This latent phase is commonly 
referred to as one of "asymptomatic left ventricular dysfunction ". 
1.1.7 From Asymptomatic Left Ventricular Systolic Dysfunction to 
Chronic Heart Failure. 
In the majority of patients who develop CHF the sequence of events begins 
with a myocardial infarction. Although many patients develop transient left 
ventricular failure in the acute phase of myocardial infarction, most patients 
recover satisfactorily (Nicod et al, 1988) despite electrocardiographic and 
cardiac enzyme evidence of substantial myocardial damage, to be left with 
asymptomatic left ventricular systolic dysfunction. In this state symptoms and 
signs of heart failure are lacking but objective assessment of cardiac function 
either non invasively, by echocardiography or radionuclide ventriculography, 
or invasively, by angiocardiography reveal depressed left ventricular 
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contractility. The left ventricular ejection fraction is the most commonly used 
parameter of left ventricular systolic function as it is associated, independently 
with prognosis (Nelson et al. 1975). The cut -off value taken to indicate 
significant left ventricular systolic dysfunction varies with the method of 
measurement and between centres but is generally less than or equal to 35- 
40%. 
The natural history of patients with left ventricular systolic dysfunction after 
myocardial infarction is not well documented. Some develop recurrent 
myocardial infarction which further compromises their left ventricular function 
often precipitating overt heart failure which may subsequently become 
chronic. Others, however, progress to the heart failure stage without further 
myocardial infarction. The heart undergoes a process of remodelling resulting 
in progressive loss of contractile function leading to symptomatic left 
ventricular systolic dysfunction (Mitchell et al. 1995). In these subjects, the 
initial infarct size is usually the dominant factor in their progression to overt 
heart failure (Moye et al. 1989). Other contributing risk factors are the 
neuroendocrine, vascular and renal responses that occur in individuals with 
left ventricular systolic dysfunction. 
Although all appears to be well in subjects with asymptomatic left ventricular 
systolic dysfunction, there is evidence to suggest that compensatory 
neuroendocrine activation is already occurring, with increases in the plasma 
levels of noradrenaline (Francis et al. 1990) and natriuretic peptides (Lerman 
et al. 1993). In addition impairment of aerobic capacity on exercise has also 
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been demonstrated in those with subclinical left ventricular systolic 
dysfunction (LeJemtel et al. 1994). 
1.1.8 Multisystem Dysfunction 
Although the primary problem in chronic heart failure is cardiac, the clinical 
syndrome is characterised by secondary multi system dysfunction which 
ultimately leads to a terminal state of multi organ failure. 
Returning to our physiological definition of heart failure, there is an important 
variable which contributes to the adequacy of oxygenation of the metabolising 
tissues and that is the blood pressure (Harris, 1987), of which the cardiac 
output is a major determinant. The reduction in cardiac output which occurs 
in left ventricular systolic dysfunction, activates a myriad of mechanisms 
which have evolved to maintain it and which, presumably, were designed to 
protect the organism from haemorrhage or the hypovolaemia of dehydration. 
Among the major components of this so called compensatory response are 
the sympathetic and renin angiotensin systems. Thus, noradrenaline is 
released, resulting in an increased heart rate and vasoconstriction. 
Decreased renal perfusion causes increased production of the powerful 
vasoconstrictor Angiotensin lI which causes sodium retention through the 
combined actions of aldosterone and increased renal sympathetic activity. 
Water retention is also enhanced by vasopressin production from the 
posterior pituitary (Francis et al, 1992). Other potent vasoconstrictors, such 
as endothelin, also contribute to the intense increase in peripheral vascular 
resistance (McMurray et al, 1992). Initially these changes are opposed by the 
cardiac endocrine system which produces atrial and brain natriuretic peptides 
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which have both natriuretic and vasodilator effects. The development of heart 
failure is an indication that these more favourable mechanisms have been 
overcome. 
Ultimately as a consequence of this extensive compensatory activity, 
structural changes take place in the vascular arterioles with increasing 
stiffness of the vessels, morphological changes occur in skeletal muscle 
(Mancini et al, 1992) and respiratory function is affected with an increase in 
physiological dead space and airways obstruction (Sullivan et al, 1988). This 
vicious circle leads to further remodelling and ventricular dilation with a 
consequent reduction in cardiac output associated with electrical instability 
which ultimately leads to death either from progressive pump failure or 
suddenly as a result of arrhythmia. 
1.1.9 Updated Definition of Chronic Heart Failure 
Consequent on our growing awareness that chronic heart failure is not just an 
isolated cardiac response to a wide range of insults but is a condition with 
numerous metabolic and endocrine effects, perhaps a more suitable definition 
for the clinician is that proposed by Packer (Packer, 1988): "Chronic heart 
failure represents a complex clinical syndrome characterised by abnormalities 
of left ventricular function and neurohormonal regulation which are 
accompanied by effort intolerance, fluid retention and reduced longevity." 
1.2 The Epidemiology of Chronic Heart Failure 
The complexity of the epidemiology of chronic heart failure (CHF) stems from 
the fact that "heart failure" is not a diagnosis per se but a syndrome made up 
of symptoms and signs produced by cardiac dysfunction. The prevalence 
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and incidence of heart failure is, therefore, critically dependent on the criteria 
used to define its presence. In addition, since the syndrome of CHF occurs 
as a consequence of cardiac disease, the prevalence and incidence vary with 
the "population" under study. Thus it will occur more commonly in populations 
with a high prevalence and incidence of its precursors, coronary heart 
disease, hypertension and diabetes. However, all studies agree that CHF is 
common and that its prevalence and incidence are rising. 
1.2.1 Prevalence of Chronic Heart Failure 
Population Studies 
Most of the epidemiological work on CHF has relied upon a "clinical 
diagnosis" for its detection. Eriksson et al, studied a cohort of 855 men, born 
in Gothenburg, Sweden, in 1913. Heart failure was detected from symptoms 
of breathlessness, signs of fluid retention and the need for digoxin and /or 
diuretic therapy. In this study, "manifest heart failure" had a prevalence of 
2.1% at 50 years, 2.4% at 54 years, 4.3% at 60 years and 10.3% at 67 years 
(Eriksson et al. 1989). Similar figures were obtained from another European 
study from Germany with a CHF prevalence of 3% of the population i.e. 1.9 
million people (Dinkel et al. 1989). 
The largest epidemiological study to look at CHF in the community is from 
North America: the Framingham Heart Study, based in a small, 
geographically selected, semi -urban US population. It commenced in 1949 
and has studied the prevalence and incidence of cardiovascular conditions in 
5209 individuals who were aged 30 -62 at enrolment. They diagnosed CHF 
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according to a clinical scoring system which included some objective 
evidence of cardiomegaly from a chest -X -ray. The reported prevalence was 
slightly lower than the European rates: 0.8% (ages 50 -59), 2.3% (ages 60- 
69), 4.9 %(ages 70 -79) and 9.1% for those greater than 80 years (McKee et 
al. 1971,Kannel et al. 1988). Presumably the Framingham Study detected 
those with more advanced CHF. 
In contrast to Framingham, which represents a rather atypical population, 
data from the National Health and Nutrition Examination Survey (N- HANES) 
described prevalence rates for CHF in the US general population of 2 %, 
based on self reported heart failure, a clinical scoring system and chest -X -ray 
appearances in a screened population of 14,407 men and women aged 25- 
74 between 1971 and 1975 (Schocken et al. 1992). 
Physician Records 
In general, population prevalence rates for CHF detected from scrutiny of 
medical records and prescription data tend to be lower, as they focus on 
those who have disease which is severe enough to have reached medical 
attention and has crossed the threshold for therapeutic intervention. 
In 1962 -65, Gibson et al measured the prevalence of CHF in the white 
population in two rural US communities. "Heart Failure " was assessed by a 
physician's diagnosis. The study estimated the population prevalence rates 
to be 0.88% in one community and 1.2% in the other (Gibson et al. 1966). 
In the UK, Parameshwar at al examined the clinical records of diuretic treated 
patients in three General practices in North West London. The prevalence of 
CHF was 0.39% overall, rising from 0.06% in those under 65 years to 2.8% in 
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those over 65 (Parameshwar et al. 1992b). Again the lower prevalence rates 
in this UK study reflect the application of "stricter" diagnostic criteria. More 
recent data from two primary care practices in Liverpool have indicated a 
higher prevalence rate of 1.5% which peaks at 8% for those over 65 years 
(Mair et al. 1996). 
1.2.2 Prevalence of Left Ventricular Systolic Dysfunction 
Studies documenting the prevalence of CHF in the general population using 
objective measures of LV function are, to date, limited for systolic dysfunction 
and almost non -existent for diastolic dysfunction. One would expect the 
prevalence rates for left ventricular systolic dysfunction to be higher in such 
studies than in those relying on clinical diagnosis as they have the potential to 
identify subjects with asymptomatic left ventricular systolic dysfunction- the 
precursor of CHF. 
The Framingham Heart Study has published M -Mode echocardiographic data 
on their "offspring" cohort i.e. the children of the original study population and 
their spouses. In 1493 men, free of cardiovascular disease, 11.4% had an 
abnormal left ventricular end diastolic dimension (LVEDD >_5.6cm) and 5.1% 
had a reduced fractional shortening (FS <30 %). This subclinical left 
ventricular dilation and systolic dysfunction was associated with an increased 
risk of new cardiovascular diseases at subsequent follow up (Lauer et al. 
1992). 
More recent work from the Framingham Study has suggested that subclinical 
LV dilation (decreased fractional shortening by M -Mode echocardiography), 
which was found in 5.2% of men and 1.9% of women in a cohort of 4744 
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subjects free of myocardial infarction, did progress to CHF: there was an 
increased hazard ratio of 1.47(95% confidence intervals, 1.25 to 1.73) for the 
development of CHF obtained in the 11 year follow up with every one 
standard deviation increment in the left ventricular end diastolic dimension 
(Vasan et al. 1997b). 
Gardin et al have also published work on subjects over 65 years, using a 
subjective assessment of left ventricular function and found it to be reduced in 
6.8% of asymptomatic men and 1.8% of women (Gardin et al. 1995). Work is 
also now available from the Rotterdam Study indicating that 3% of subjects 
over 55 years have a fractional shortening <25% (Mosterd et al. 1997). 
1.2.3 Prevalence of Diastolic Dysfunction. 
Left ventricular dysfunction can, of course be due to diastolic dysfunction (or a 
combination of systolic and diastolic dysfunction). Indeed 36 -42% of patients 
who have CHF diagnosed on clinical criteria have normal systolic function 
(Dougherty et al. 1984, Soufer et al. 1985). Thus, the population prevalence 
of diastolic dysfunction may be about forty percent of that attributable to 
systolic dysfunction. However, there is, as yet, no information on the 
prevalence of diastolic dysfunction in the " general population ". 
1.2.4 Chronic Heart Failure and Left Ventricular Systolic Dysfunction In 
"High Risk" Populations 
It is in post MI populations that the greatest prevalence rates for CHF are to 
be found. In the Framingham Study, 18% of patients with myocardial 
infarction developed CHF within five years; a ten year adjusted risk of heart 
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failure ten to twenty times that of the general population (Kannel et al. 1979, 
Kannel, 1987). 
This study predated the use of thrombolytic therapy, which now results in 
more patients surviving acute myocardial infarction (Yusuf et al. 1988). In a 
more recent study of all patients with myocardial infarction in a District 
General Hospitai, heart failure developed, even if only transiently, in at least 
35% (Stevenson et al. 1993). 
Similarly, in the post thrombolytic era in the US, one of the largest post 
myocardial infarction trials of angiotensin converting enzyme inhibitors, the 
SAVE Trial, found that 40% of their population had evidence of left ventricular 
systolic dysfunction post MI ( LVEF <40 %), 14% had CHF and 25% had 
asymptomatic left ventricular systolic dysfunction (Pfeffer et al. 1992). 
Similar figures were obtained in a European Post MI trial (TRACE) with 39% 
of subjects having a wall motion score index <_1.2 (Kober et al. 1994). 
Not surprisingly, the prevalence of CHF is also higher in those at most risk of 
developing myocardial infarction i.e. individuals with coronary artery disease. 
Objective information on LV function is now available from the Framingham 
Study, showing that LV dilation is present in 19 % of women and 23.2% of 
men with proven coronary artery disease (Galderisi et al. 1992). 
1.2.5 Incidence of Chronic Heart Failure 
At thirty four years of follow up in the Framingham Heart Study, the incidence 
rate for CHF was 2/1000 in persons aged 45 -54 years rising to 40/1000 in 
men aged 85 -94 (McKee et al. 1971). Using similar diagnostic criteria, 
Eriksson et al reported incidence rates for "manifest heart failure" for men of 
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1.5/1000, 4.3/1000 and 10.2/1000 at ages 50 -54, 55 -60 and 61 -67- figures 
similar to Framingham (Eriksson et al. 1989). More recently Remes et al 
(using the Framingham clinical criteria for diagnosis) have reported the 
incidence of heart failure in rural Eastern Finland in men aged 45 -74 at 
4.1/1000- very consistent with the above studies (Remes et al. 1992). There 
are, however, no incidence data for heart failure diagnosed objectively by 
measurement of LV function. 
1.2.6 Aetiology of Chronic Heart Failure and Left Ventricular Systolic 
Dysfunction 
As alluded to earlier there is a myriad of possible causes of CHF and its 
principal antecedent, left ventricular systolic dysfunction. Their relative 
importance varies principally with geography such that it would be Chagas 
Disease in South America and hypertension in North American Blacks. There 
are four main data sources on the aetiology of left ventricular systolic 
dysfunction: (1) Population -based studies, (2) Physician records, (3) Hospital 
admissions and discharges, (4) Controlled Clinical Trials. 
Population -based Studies 
The Framingham Heart Study on publication of its 32 year follow up in 1971 
claimed that hypertension was found in 77% of all the cases of CHF identified 
in contrast to ischaemic heart disease (IHD) which was present in only 30- 
45% (McKee et al. 1971). Throughout the 1980s there appeared to be a shift 
in the aetiology of CHF in the cohort. When the 44 year follow up data were 
made available, IHD had superseded hypertension and accounted for 55% of 
cases (although 31% had coexistent IHD and hypertension). Hypertension on 
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its own accounted for only 24% of the CHF discovered (Ho et al. 1993a). 
However that finding has been challenged in the latest Framingham analysis 
where the population attributable risk for hypertension and CHF was quoted 
at 39% for men and 59% for women (Levy et al. 1996). This apparent swing 
back to hypertension, however, should be treated with caution as the 
definition of hypertension in the Framingham study has changed from a blood 
pressure of >160 /95mmHg until the 1980s when it dropped to >140/90mmHg. 
This will obviously increase its prevalence in the cohort. 
Population -based studies other than Framingham have confirmed the 
dominance of IHD in the causation of CHF. Eriksson reported that 55% of 
those with manifest CHF had IHD, 48% had hypertension (Eriksson et al. 
1989). The dual aetiology was also important with 79% having both risk 
factors. Interestingly, in this study, hypertension appeared to be a more 
potent correlate of latent CHF occurring in 52% of cases compared to 25% for 
IHD. IHD has also been confirmed as the principal aetiology of the heart 
failure identified in another European Population in Eastern Finland, occurring 
in 61% of cases (Remes et al. 1992). 
Physician Records 
Mair et al have confirmed from their study in another U.K urban population 
that IHD is the principal aetiology of the CHF identified in primary care (Mair 
et al. 1996). 
It should be borne in mind that the aetiology of left ventricular systolic 
dysfunction from the above data sources is not completely accurate as the 
occurrence of dilated cardiomyopathy cannot be established due to the 
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impracticality of performing coronary angiography in such epidemiological 
studies. 
Hospital Admissions 
A similar pattern to the above has been confirmed in the UK for hospital 
admissions: of admissions to a district general hospital with CHF over a 6 
month period with CHF, 41% had IHD and 6.4% were hypertensive 
(Parameshwar et al. 1992a). 
Racial differences, even within so called Western, industrialised societies are 
also important. In a recent hospital -based study in the US, hypertension was 
the most common cause of symptomatic left ventricular dysfunction in blacks, 
IHD accounting for only 23% (Mathew et al. 1996). 
Controlled Trials 
Moving into the more select arena of clinical trials, Teerlink et al published a 
review of CHF Trials during 1989 -90 involving 1861 patients. This confirmed 
the ascendancy of IHD in the aetiology of CHF, with 50.3% of enrolled 
subjects having this as the main cause ( Teerlink et al. 1991). As expected in 
the hospital setting, idiopathic dilated cardiomyopathy gained more 
prominence accounting for 18.2% of cases. The major CHF treatment trials 
all have had the majority of their patients in the ischaemic category: 44% in 
VeHeft I (Cohn et al. 1986) and 73% in CONSENSUS 1 (Swedberg et al. 
1987). 
The only information we have for the aetiology of left ventricular systolic 
dysfunction comes from these trials. Regarding symptomatic left ventricular 
systolic dysfunction: 71% of subjects recruited into the treatment arm of 
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SOLVD had IHD, 42% were hypertensive (The SOLVD Investigators, 1991) 
and in the VeHeft II study, 53% had IHD, 48% were hypertensive and 35% 
were felt to have alcoholic cardiomyopathy (Cohn et aI. 1991). 
Information on the causation of asymptomatic left ventricular systolic 
dysfunction is very limited. There is some available from the prevention arm 
of SOLVD showing a similar pattern to symptomatic left ventricular systolic 
dysfunction in that 83% of patients had IHD, 37% were hypertensive and 9% 
were thought to have idiopathic cardiomyopathy (The SOLVD Investigators, 
1992). 
Although the absolute contribution of the various aetiologies varies a little in 
the data discussed, the general impression is that IHD is the most important 
cause of CHF and left ventricular systolic dysfunction, hypertension also has 
a major role, the two often coexist and there appears to have been a shift 
from hypertension to IHD as the principal aetiology over the last 25 years. 
1.2.7 Importance of Chronic Heart Failure and Left Ventricular Systolic 
Dysfunction 
The importance of CHF and its antecedent left ventricular systolic dysfunction 
can be considered by examining their effects on mortality, morbidity and cost. 
Mortality: Population -based studies 
Heart Failure is a fatal condition with a mortality which exceeds many 
malignancies. In the Framingham Study the probability of dying within five 
years of the onset of heart failure was 62% for men and 48% for women 
(McKee et al. 1971). "The Men Born in 1913" study provided information on 
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mortality rates in less severe heart failure with a five year mortality rate of 
26% in men with mild to moderate CHF and 10% in those with "latent heart 
failure" (Eriksson et al. 1989). The more recent NHANES survey has 
confirmed the grave prognosis with a 10 yr. mortality of 54% in men and 38% 
in women over the 25 -74 age group to which this thesis pertains (Schocken et 
al. 1992). 
Mortality of CHF and Left Ventricular Systolic Dysfunction: Clinical 
Trials 
Recent therapeutic advances, in particular, the angiotensin -l- converting 
enzyme inhibitors (ACED, have made only a modest impact on that prognosis. 
In the CONSENSUS 1 Study, one year mortality in the NYHA Class IV CHF 
patients treated with enalapril was still 36% compared to 52% in the placebo 
group (Swedberg et al. 1987) In the same vein, NYHA Class II -III patients in 
the SOLVD Treatment Trial placebo group had a mortality of 40% at four 
years into follow up (The SOLVD Investigators, 1991). The treatment arm 
mortality remained considerable (though significantly reduced) at 35 %. The 
post MI LV systolic dysfunction trial TRACE still exhibited high mortality rates 
of 42.3% (placebo group) and 34.7% (ACEI group) at 4 years (Kober et al. 
1995). In contrast, the annual mortality in patients with asymptomatic left 
ventricular systolic dysfunction is only 4% (The SOLVD Investigators, 1992) 
which gives considerable hope that earlier detection and treatment of CHF in 
its asymptomatic phase will be of benefit. 
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Mortality of Diastolic Dysfunction 
Epidemiological data regarding the natural history of diastolic heart failure is 
very limited, as all the recent heart failure treatment trials have only studied 
patients with systolic dysfunction. In five years of follow up in the Veterans 
Administration Co- operative Study Group (The Ve -Heft Study) (Cohn and 
Johnson, 1990), no significant decline in ejection fraction occurred in the 
subgroup with normal systolic function. The group with diastolic dysfunction 
had a significantly lower annual mortality rate of 8% versus 19% in those with 
a reduced ejection fraction. However, recent population -based data from the 
Mayo clinic have suggested that the outlook from diastolic dysfunction is no 
better than that of systolic dysfunction (Senni et al. 1997). 
Morbidity 
CHF is associated with considerable morbidity. The annual hospitalisation 
rate for those with CHF approaches 45% (The SOLVD Investigators, 1991). 
Parameshwar et al found that CHF accounted for 4.9% of all medical and 
geriatric admissions in a District General Hospital in North West London 
(Parameshwar et al. 1992a). Once in hospital, these patients had a long stay 
with an average hospitalisation time of 16.7 days. Similar data for Scottish 
Hospitals revealed heart failure to account for 4.1% of all general medical and 
cardiology admissions (McMurray et al. 1993). 
Data are available for hospitalisation for CHF from the clinical trials for 
patients with symptomatic left ventricular systolic dysfunction showing that 
36.6% of placebo subjects in the SOLVD treatment arm were hospitalised 
over a four year period as compared with 25.8% in the ACEI group (The 
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SOLVD Investigators, 1991). For asymptomatic left ventricular systolic 
dysfunction, the rates are less with 21.5% of the placebo group and 14.5% of 
the ACEI group requiring admission for CHF over 4 years in the prevention 
arm of SOLVD (The SOLVD Investigators, 1992). Similarly in post MI left 
ventricular systolic dysfunction from the SAVE Study, 17% of placebo and 
14% of captopril treated patients were admitted over a four year period 
(Pfeffer et al. 1992). 
In addition, CHF causes more impairment of quality of life than any other 
chronic medical disorder (Stewart et al. 1989). In the treatment arm of SOLVD 
(Gorkin et al. 1993) and in the "Men Born in 1913 Study" mild and moderate 
CHF was associated with less energy, lower fitness levels and more physical 
complaints (Eriksson et aI. 1988). Consequent to its high morbidity and high 
hospitalisation rate, it is no surprise that CHF is a health problem with major 
economic implications for health care delivery systems (McMurray and Hart, 
1993). In the UK in 1996, the annual expenditure for CHF was £360 million, 
which was 1.2% of total health care expenditure, 60% of which was 
attributable to hospitalisation (McMurray and Davie, 1996). 
1.2.8 Trends In CHF Epidemiology 
Epidemiological studies agree that, despite differences in definition, incidence 
and prevalence rates, heart failure is a growing world -wide health problem. 
This is, in part, due to the increasing longevity of the population in 
industrialised countries. Two reports from the US. suggest that hospitalisation 
rates for CHF have been rising (Gillum, 1987,Ghali et al. 1990). Similarly, in 
Scotland, the number of hospitalisations for CHF rose by 6% between 1980- 
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1990, such that the number of admissions for CHF now nearly equals those 
for myocardial infarction (McMurray et al. 1993). 
1.3 Exercise Testing in Heart Failure 
The definition of heart failure used at the outset of this thesis alludes to a 
central pump failing to respond to the needs of the tissues, principally, in their 
requirement for oxygen. Consequently, the . manifestations of pump 
malfunction in heart failure are more pronounced on exercise. The cardiac 
response to exercise, therefore, is in some ways fundamental to any 
pathophysiological dissection of CHF. 
Thus, the cardinal symptoms of CHF, breathlessness and muscle fatigue 
occur, at least initially, on exertion. We would therefore expect exercise 
testing to be as valuable for the clinician, as it is for the physiologist in the 
diagnosis and assessment of heart failure. 
1.3.1 Oxygen Uptake and Left Ventricular Dysfunction 
The best indicator of aerobic capacity, the maximal oxygen uptake (VO2 max), 
measured during incremental cardiopulmonary exercise testing, is reduced in 
subjects with symptomatic left ventricular systolic dysfunction. However, a 
true maximal oxygen uptake, where the work rate of the subject increases 
despite a plateau in oxygen consumption is rarely achieved in heart failure 
subjects (Lipkin et al. 1985). Since these patients generally stop prior to this 
with muscle fatigue or breathlessness, the peak oxygen uptake is more 
usually quoted. The peak oxygen uptake is similarly reduced in subjects with 
symptomatic left ventricular systolic dysfunction. It reflects the severity of 
symptoms and is reproducible (Weber et al. 1984). 
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Not only is the peak oxygen uptake reduced in symptomatic left ventricular 
systolic dysfunction, it is now also known to be diminished in asymptomatic 
left ventricular systolic dysfunction. Data from the prevention arm of the 
SOLVD trial show that asymptomatic patients, on no cardiac medication, who 
had left ventricular ejection fractions < 35% had a significantly reduced peak 
VO2 compared to controls (LeJemtel et al. 1994). Indeed, the mean exercise 
duration in subjects with asymptomatic left ventricular systolic dysfunction 
was 291 seconds, nearly five minutes less than normal, age and sex - 
matched controls. 
Exercise capacity is also reduced in diastolic heart failure. Kitzman and 
colleagues have studied subjects who have at least one episode of 
symptomatic heart failure who had preserved LV systolic function, and found 
they had a diminished peak VO2 compared to normal controls (Kitzman et al. 
1991). 
Exercise testing would, therefore, appear to be useful in the evaluation of 
heart failure, be it symptomatic or asymptomatic or due to systolic or diastolic 
dysfunction. However, there are some drawbacks which have to be borne in 
mind when considering its role in the assessment of CHF. These relate to the 
poor correlation between measures of exercise capacity and other commonly 
used methods of classifying CHF. 
1.3.2 Relationship Between Measures of Effort Capacity and Other 
Markers of Chronic Heart Failure. 
Exercise variables correlate poorly with the New York Heart Association 
Category (Franciosa et al. 1979). In addition, there is, at best, only a weak 
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relationship between resting haemodynamic measures of LV function (cardiac 
index, pulmonary capillary wedge pressure or angiographic ejection fraction) 
and measures of exercise performance (Franciosa et al. 1981). Finally, there 
is essentially no relationship between commonly used resting 
echocardiographic methods of determining LV function, the LV ejection 
fraction or left ventricular end diastolic dimension, and exercise capacity 
(Weber et al. 1984). 
The poor relationship between measures of LV function and effort capacity in 
left ventricular systolic dysfunction is hardly surprising as many factors other 
than central pump function affect exercise capacity in heart failure subjects. 
We know that CHF subjects have an abnormal ventilatory response to 
exercise with an increase in dead space ventilation (Sullivan et al. 1988). 
There are also changes in the periphery with alterations in skeletal muscle 
biochemistry leading to an early acidosis on exercise testing (Wilson et al. 
1985). There are effects of secondary physical deconditioning causing 
changes in skeletal muscle morphology (Mancini et al. 1992, Starling et al. 
1981). There is impaired nutritive flow and an increase in peripheral vascular 
resistance (Zelis et al. 1974). 
Despite these drawbacks, maximal or peak oxygen uptake measured from an 
incremental exercise protocol, in ambulant patients, is widely accepted to a 
good, if not, the best measure of the severity of CHF. Although resting LV 
function measurements do not equate with exercise parameters, functional 
classifications of maximum oxygen uptake do correlate well with exercise 
haemodynamic measures of LV function. Weber and colleagues have 
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classified heart failure subjects into four categories based on maximal oxygen 
uptake (Weber and Janicki, 1985). They found, that on exercise testing, 
these categories correlated well with cardiac index and wedge pressure. 
Patients in the poorest oxygen consumption category had a blunted increase 
in cardiac index with exercise, compared to those with less impairment of 
aerobic capacity. They also had a higher wedge. pressure at peak exercise 
compared to those groups with superior oxygen uptake. Oxygen uptake is, 
therefore, useful in grading the severity of CHF. 
Thus, exercise testing does have a diagnostic role in evaluating and clarifying 
symptoms in CHF and in grading its severity. This can be done either by the 
measurement of maximal or peak oxygen uptake or by measuring exercise 
duration, provided that in the exercise protocol used, exercise duration 
adequately reflects oxygen consumption. 
The correlation between exercise duration and oxygen consumption varies 
between exercise protocols. When oxygen consumption is plotted against 
exercise duration in both normal volunteers and CHF subjects using the 
Standardised Exponential Exercise Protocol (STEEP) (both for normals and 
CHF subjects) there is a good linear relationship between the values. Using 
such a protocol it would be possible to regard exercise duration as a 
reasonable surrogate for peak oxygen uptake (Riley et al. 1992). This is the 
protocol used in this thesis. 
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1.3.3 Role in Assessment of the Aetiology of Left Ventricular Systolic 
Dysfunction 
The management of CHF depends on its aetiology. Therefore, a cause 
should always be sought. Exercise testing has an obvious role in the 
assessment of the main aetiological factor in left ventricular systolic 
dysfunction, ischaemic heart disease. 
As well as guiding medical management of ongoing myocardial ischaemia, it 
is also helpful in detecting those patients who would benefit from 
revascularisation surgery. Bounous and colleagues have demonstrated, in 
nine years of follow up, that in subjects with left ventricular systolic 
dysfunction, whether it is mild, moderate or severe who have severe coronary 
artery disease, there is a survival benefit to be gained from revascularisation 
surgery compared to medical management (Bounous et al. 1988). 
1.3.4 Role in Prediction of Prognosis 
Exercise testing also has a role in estimating prognosis in heart failure. 
The poorer survival of CHF subjects who have reduced effort tolerance on 
exercise testing has been confirmed by some of the larger heart failure 
treatment trials. In both the Ve Heft trials, with, in total over 1400 men, 
maximum oxygen consumption and exercise duration were independent 
predictors of mortality in up to 5 years of follow up (Cohn et al. 1993). 
Roul and colleagues have studied 75 subjects with CHF in NYHA categories 
Il and Ill and found that those who had a peak oxygen uptake of less than or 
equal to 14 mis /kg /min have a significantly higher mortality than those with a 
greater aerobic capacity (Rout et al. 1994). The figure of 14mis /kg /min has 
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been suggested by Mancini and others as one at which cardiac 
transplantation should at least be considered (Mancini et al. 1991). 
Although in this study peak oxygen consumption was the best predictor of 
mortality exercise duration also correlated with death. The authors suggested 
that patients could be followed up by exercise duration providing the exercise 
protocol satisfactorily reflected oxygen consumption. 
Although the relationship between exercise parameters and left ventricular 
systolic dysfunction has been extensively studied in patient populations, there 
is no population -based study examining this. The work presented in Chapter 
5 addresses this issue. 
1.4 The Natriuretic Peptides 
The natriuretic peptides comprise a family of three hormones, principally 
produced by the heart. They cause natriuresis, diuresis and vasodilation and 
play a major role in sodium and volume homeostasis in health and disease. 
The first of these peptides to be discovered, and the most extensively studied, 
is atrial natriuretic peptide. It is a 28 amino acid peptide, synthesised and 
secreted, predominantly by the cardiac atria (Kangawa and Matsuo, 1984). It 
is stored in the myocyte as a 125 amino acid prohormone and on secretion, is 
cleaved into an N- terminal fragment (N -ANP) of 98 amino acids and the 
biologically active C- terminal -ANP (Singer et al. 1996). The half life of ANP is 
considerably shorter (2.5 mins) than N -ANP. N -ANP is thus more easily 
measured (Singer et al. 1996, Wei et al. 1993). 
A second natriuretic peptide, brain natriuretic peptide (BNP), was discovered 
in 1988 (initially named owing to its first description in porcine brain). Its 
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predominant site of origin has subsequently been shown to be the ventricular 
myocardium (Yasue et al. 1994,Yoshimura et al. 1993). It is a 32 amino acid 
peptide similar in structure to ANP (Mukoyama et al. 1990). 
The third peptide, CNP, is mainly 
found in the central nervous system and vascular endothelium and appears 
to have limited natriuretic and vasodilator properties (Hunt et al. 1994). 
1.4.1 Production 
The main trigger for the production of both ANP and BNP is stretching of the 
atrial and ventricular walls (Kinnunen et al. 1993). While there is a 
relationship between atrial pressure and plasma ANP concentration, atrial 
wall stress and stretch are the predominant stimuli for ANP release (Schuster 
et al. 1995). Similarly, BNP is secreted, principally by the ventricles in 
response to ventricular dilation (smaller amounts are also released from the 
atria) (Yasue et al. 1994,Yoshimura et al. 1993). Both ANP and BNP are 
detectable in the plasma of normal subjects at picomolar concentrations. 
1.4.2 Exertion of Action 
The natriuretic peptides produce their actions via three different receptors; A, 
B and C (Nakao et al. 1992). The A and B receptors cause increased 
production of cyclic GMP. The C receptor acts as a clearance receptor but 
may also exert biological actions via mechanisms other than cGMP (Luscher, 
1994). All three receptors are widely distributed and are found in the kidney, 
vascular endothelium, adrenals, the central nervous system as well as in the 
heart (Califf and Bengtson, 1994). 
39 
1.4.3 Clearance 
Natriuretic peptides are removed from the circulation by two main 
mechanisms, firstly via receptor mediated endocytosis and secondly through 
degradation by the enzyme neutral endopeptidase (Townend and Littler, 
1993). 
1.4.4 Actions 
Both ANP and BNP produce natriuresis and diuresis by a direct effect on the 
collecting duct and through actions on the glomerular and tubular cells. They 
also inhibit the actions of anti -diuretic hormone (Sunman and Sever, 1993). 
Importantly, they also interact with other neurohormonal mechanisms. ANP is 
known to antagonise the renin -angiotensin -aldosterone system by inhibiting 
renin production, decreasing angiotensin converting enzyme activity and 
inhibiting aldosterone release by angiotensin II (Kurtz and Della Bruna, 1986, 
Berning et al. 1992, Gregor et al. 1984). ANP also decreases sympathetic 
nervous system activity (Dubin et al. 1990) (Interestingly BNP does not and 
can increase noradrenaline levels; but its other actions are similar). Both 
ANP and BNP inhibit the release of the potent vasoconstrictor, endothelin 
(Akhras and Jackson, 1991). The effects of ANP and BNP within the heart 
are less well documented but ANP is known to be a coronary vasodilator. 
In contrast with the other hormones, CNP, is thought to act as a 
neurotransmitter in central cardiovascular control systems and may exert 
paracrine effects on vascular growth. It is not a vasodilator or diuretic 
(Maggioni et al. 1991). 
40 
1.4.5 Pathophysiology 
Both the C and N terminals of ANP are predominantly secreted by the atria in 
response to the stretch which accompanies the increased left atrial pressure 
associated with the full blown syndrome of chronic heart failure (Wei et al. 
1993). The circulating concentrations of both these peptides are raised in 
patients with symptomatic left ventricular systolic dysfunction i.e. CHF 
(Gottlieb et al. 1989). The levels of N -ANP are higher, reflecting its reduced 
renal clearance. More recently BNP concentrations have also been shown to 
be elevated in patients with symptomatic left ventricular systolic dysfunction 
(Yasue et al. 1994). The absolute ANP and BNP levels correlate with other 
commonly used markers of the severity of CHF including haemodynamic 
parameters, indices of systolic function and the New York Heart Association 
Class (Gottlieb et al. 1989, Yasue et al. 1994). Mean plasma concentrations 
of N -ANP and BNP are also raised in subjects with asymptomatic left 
ventricular systolic dysfunction (Lerman et al. 1993, Motwani et al. 1993). 
Other conditions are also associated with increases in the natriuretic peptides 
(though much smaller) including, left ventricular hypertrophy (BNP) (Kohno et 
al. 1992), diastolic dysfunction (BNP) (Clarkson et al. 1996), renal impairment 
(both ANP and BNP) and advancing age (both ANP and BNP) (Wei et al. 
1993). 
The finding of increased circulating levels of these hormones in left ventricular 
systolic dysfunction has led to speculation about their usefulness in the 
diagnosis, prognosis, therapeutic monitoring and modulation of this condition. 
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1.4.6 Diagnosis: in Patient Groups 
Symptomatic Left Ventricular Systolic Dysfunction 
Symptoms and signs lack both sensitivity and specificity in the diagnosis of 
CHF. In contrast to this, natriuretic peptides have been shown to be useful in 
differentiating heart failure as the cause of dyspnoea in patients presenting 
with acute breathlessness (Davis et al. 1994). BNP appears to be a better 
diagnostic marker than ANP: a BNP concentration of >_22pmo1/I giving a 
sensitivity of 93% for diagnosing heart failure and for the detection of left 
ventricular systolic dysfunction, it had a sensitivity of 80% with a specificity of 
70 %. 
Asymptomatic Left Ventricular Systolic Dysfunction 
Both N -ANP (Lerman et al. 1993) and BNP (Motwani et al. 1993, Omland et 
al. 1996b) are also raised in patients with asymptomatic left ventricular 
systolic dysfunction. Lerman et al found that N -ANP at a concentration of 
>54pmol /I had a sensitivity of 90% and specificity of 92% for detecting 
symptomless left ventricular systolic dysfunction in subjects undergoing 
diagnostic cardiac catheterisation (Lerman et al. 1993). 
Left Ventricular Systolic Dysfunction (Symptomatic or Asymptomatic) 
Post Myocardial Infarction 
Motwani et al (Motwani et al. 1993) demonstrated that plasma BNP can 
identify those with significant left ventricular systolic dysfunction post 
myocardial infarction who would benefit from ACE inhibition. This work has 
been corroborated by others (Choy et al. 1994, Omland et al. 1996a) 
indicating that BNP has a sensitivity of 84% in detecting left ventricular 
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systolic dysfunction post infarct (greater than that of ANP which was 64% 
sensitive). These peptides, therefore, have the potential to assist in risk 
stratification post MI to determine groups likely to benefit from ACE inhibition. 
1.4.6 Prognosis 
Giving the apparent relationship between BNP concentration and left 
ventricular function, it is perhaps not surprising that BNP has been shown to 
be of value in predicting prognosis in cardiovascular disease. In a recent 
study carried out in subjects post acute myocardial infarction, BNP was 
strongly and independently associated with long term survival (Omland et al. 
1996a). This work has now been extended to the general population, where 
BNP has been shown to predict mortality in elderly subjects (85 years) 
whether or not they have cardiovascular disease (Wallen et al. 1997). 
Atrial natriuretic peptide (particularly N -ANP) has also been shown to predict 
outcome following myocardial infarction in terms of survival or the 
development of heart failure (Hall et al. 1994). However, when C -ANP, N- 
ANP and BNP have been compared in this regard, although all three peptides 
are powerful predictors of mortality on univariate Cox proportional hazards 
modelling, in a multivariate model, only BNP provided additional prognostic 
information beyond the left ventricular ejection fraction (Omland et al. 1996a). 
Thus, elevated concentrations of natriuretic peptides and in particular, BNP 
should help to identify those at highest risk who require specific treatment. 
1,4.7 Monitoring of Treatment 
As levels of the natriuretic peptides correlate with other commonly used 
markers of the severity of CHF and left ventricular systolic dysfunction, they 
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may also have a role in guiding the effectiveness of therapy in left ventricular 
systolic dysfunction. There is evidence showing that treatment with 
angiotensin converting enzyme inhibitors (ACE inhibitors) reduces atrial 
natriuretic peptide levels early after myocardial infarction and during long term 
treatment in left ventricular systolic dysfunction (Bonarjee et al. 1995, 
McMahon et al. 1983). More limited data is available for BNP indicating lower 
plasma levels in subjects with left ventricular systolic dysfunction post MI 
treated with ACE inhibition (Motwani et al. 1993). 
Murdoch et al have also conducted a small study randomising subjects with 
CHF to either standard therapy guided by clinical parameters or to 
adjustments in treatment driven by BNP levels (aiming to normalise plasma 
BNP). While there was no significant difference in haemodynamics between 
the two groups, those receiving BNP driven therapy had a more favourable 
neurohormonal profile (Murdoch et al 1997a). 
Much work is needed before natriuretic peptides are in routine clinical use in 
monitoring the treatment of left ventricular systolic dysfunction but preliminary 
work suggests that they may have a role in the future as "biochemical Swan 
Ganz catheters" or HbA1 equivalents. 
1.4.8 Therapeutic Modulation 
As the endogenous response of the body to fluid overload, the natriuretic 
peptide system is also being exploited therapeutically in the management of 
left ventricular systolic dysfunction. This approach may have advantages 
over conventional therapy. Unlike loop diuretics and many vasodilators, 
natriuretic peptides cause inhibition rather than stimulation of the renin 
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angiotensin system. In addition, ANP may also reduce cardiac ischaemia and 
modulate vascular growth. The neutral endopeptidase inhibitor, candoxatril, 
which increases both ANP and BNP concentrations has been shown to 
produce a natriuresis in CHF similar to frusemide but with a more beneficial 
neurohormonal profile (Northridge et al. 1992). A larger, longer term, study 
using candoxatril also produced an improvement in effort capacity in subjects 
with CHF (Newby et al 1997). In addition, intravenous infusions of both ANP 
(Cody et al. 1986) and BNP (Marcus et al. 1996) cause diuresis, natriuresis 
and alter haemodynamics favourably in heart failure. 
The natriuretic peptide system forms a complementary cardiovascular control 
system which offsets the activity of the renin -angiotensin -aldosterone system 
in left ventricular systolic dysfunction. Our knowledge, so far, of the peptide 
hormones themselves points to them having important roles in the diagnosis, 
prediction of prognosis and in treatment monitoring of left ventricular systolic 
dysfunction. The usefulness of these peptides to detect left ventricular systolic 
dysfunction in the general population is, however, unknown and is the basis 
of the work presented in Chapter 6 of this thesis. 
1.5 The Angiotensin -l- Converting Enzyme Insertion /Deletion 
Polymorphism 
Activity of the zinc metalloprotease, angiotensin converting enzyme, produces 
the octapeptide angiotensin H which is thought to have an important role in 
the pathophysiology of heart failure, cardiac remodelling post myocardial 
infarction and the development of left ventricular hypertrophy. The gene 
encoding the angiotensin converting enzyme is located on Chromosome 17q 
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(Hubert et al. 1991). It contains a polymorphism (ACE I /D) consisting of the 
presence or absence of a 287bp fragment (Alu repetitive sequence) in intron 
16 (Rigat et al. 1992). The polymorphism most probably represents a neutral 
marker for a functional variant explaining 25 -44% of the interindividual 
variability of plasma ACE activity (Cambien et al. 1994). Homozygous 
subjects for the D allele have circulating ACE concentrations nearly double 
that of II individuals (Cambien et al. 1994). 
1.5.1 Myocardial Infarction 
Cambien et al (Cambien et al. 1992) first reported on the association between 
the DD genotype and the risk of MI in a large case -control study from three 
French and one Northern Irish MONICA centres: the prevalence of DD was 
1.34 times higher in the cases than the controls. Interestingly, the odds ratio 
was higher in "low risk" subjects (those with lower body mass indices and 
apolipoprotein B levels). Several other studies have confirmed this 
observation, including an autopsy study on subjects dying suddenly with MI in 
Belfast (Evans et aI. 1994). However, not all reports are in agreement: a 
relatively small Norwegian study found the DD genotype to be less common 
in men with MI (Bohn et al. 1993). 
Other studies have had broader endpoints including angina and "prevalent 
coronary heart disease" and have found mixed results regarding the 
association of the DD genotype with increased risk (Meittinen et al. 1994, 
Mattu et al. 1995). In particular two large studies from the US have provided 
divergent results. The Physicians Health Study (Kreutz et al. 1993) reported 
no association of the DD genotype with MI or revascularisation. Whilst this is 
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a prospective study, it is however, a highly selected population (5% of invitees 
were recruited) with a low event rate. An angiographic study from Utah 
(Ludwig et al. 1993), did find the DD genotype to be increased in men with a 
history of prior MI, again with the relationship being stronger in those 
traditionally at low risk. Several other European Studies support the DD risk 
association (Ossei- Gerning et al. 1995, Ahnve et al. 1995) and several from 
Japan suggest a much stronger association of IHD with the DD genotype 
(Zhao et al. 1994, Nakai et al. 1994). 
With evidence looking slightly stronger for the association with the I/D 
polymorphism and MI risk, it has been suggested that publication bias has 
led to a false assumption. Recent evidence has shown that positive studies 
tend to be small and the larger studies, negative (Samani et al. 1996). A 
study conducted in this thesis allows further dissection of the association of 
the DD genotype with IHD and MI in a large cross -sectional, study population. 
1.5.2 Hypertension 
At the population level, hypertension is one of the most important risk factors 
for CHF. While there is relatively little evidence linking essential hypertension 
with the ACE genotype, only one small Australian study being positive 
(Harrap et al. 1993), there is now good evidence to link electrocardiographic 
LVH (Schunkert et al. 1994) and LV mass ( Perticone et al. 1997) with the DD 
genotype. 
1,5.3 Cardiac Failure 
There is only the indirect evidence presented above to indicate a possible role 
for the ACE I/D polymorphism in heart failure, by assuming that its association 
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with IHD and hypertension, the main risk factors for CHF, will implicate it in 
their final manifestation. There is one report showing that the DD genotype 
was more frequent in subjects with ischaemic and dilated cardiomyopathy 
(Raynolds et al. 1993). There is, however, no population -based work on left 
ventricular systolic dysfunction relating to the ACE genotype. Part of this 
thesis addresses that question. 
1.6 Aims of the Thesis 
The introduction has highlighted the need for a substantial reappraisal of the 
epidemiology of CHF in the 1990s, not only for scientific purposes but to 
inform modern medical practice. The previous large population -based studies 
have relied on a clinical diagnosis of CHF, which we know can be unreliable. 
Epidemiological data on left ventricular systolic dysfunction is very limited, 
and there is none in the world on asymptomatic left ventricular systolic 
dysfunction, using a meaningful echocardiographic measurement. In addition, 
the aetiology of CHF may have changed since the major studies reported. 
With this in mind the aims of this thesis were to: 
1 Determine the prevalence of left ventricular systolic dysfunction, both 
symptomatic and asymptomatic in an urban population (Chapter 3) 
2 Ascertain the aetiology of the left ventricular systolic dysfunction, identified 
(Chapter 4) 
3 Examine the effect of left ventricular systolic dysfunction on effort capacity 
(Chapter 5) 
4 Test the usefulness of the natriuretic peptides in detecting left ventricular 
systolic dysfunction. (Chapter 6) 
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5 Study the relationship between the ACE I/D polymorphism, ischaemic heart 






2.1.1 Parent Cohort 
The theoretical study population was all men and women aged 25 -74, living in 
the City of Glasgow, North of the River Clyde (Tunstall -Pedoe et al. 1994, 
Smith et al. 1990). A random sample of this population were invited to attend 
the Third Glasgow MONICA Population Coronary Risk Factor Survey in 1992 
(MONICA 3), using a two stage random sampling method. Firstly 30 family 
practitioners were randomly selected from the 210 in the area. Secondly, 
patients were randomly selected from each ten year age /sex band from 25 -74 
years in proportion to the doctor's list of patients. Oversampling to allow for 
non response was carried out. The response rate in that study was 67 %. 
2.1.2 Study Cohort 
To recruit 30 family practitioners, 36 were invited to participate. Two were 
excluded ( <200 patients each) and four refused. A total of 1952 men and 
1889 women were invited to attend the Third GlasgoAr MONICA Coronary 
Risk Factor Survey (MONICA 3). Three hundred and thirty nine men and 250 
women were not resident at the address held by the family practitioner and 
remained untraceable despite various searches; 138 men and 72 women 
were otherwise ineligible because of age or place of residence. Nine hundred 
and twenty seven men and 1031 women finally attended- a response rate 
among those eligible of 61.8% for men and 65.8% for women. The response 
rate varied by age, sex and social class with the youngest and least affluent 
groups in both sexes having the poorest response. The social class structure 
of the responders was similar to that of the population (which is skewed 
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towards the socioeconomically deprived) and the response rate is similar to 
that in other epidemiological studies in urban populations (Murray et al. 1995). 
Of the 1993 MONICA 3 responders invited to the present study, 1640 
attended (83 %). The response rate was 87% for men and 83% for women. 
This present sample is representative of the parent cohort in all relevant 
criteria with the exception that the attendees were more affluent and there 
were fewer smokers. The prevalence of coronary heart disease and 
hypertension was the same as that of the parent cohort. 
2.1.3 Response Rate by age and sex. 
The numbers attending did not differ significantly between the age sex groups 
with the exception of a statistically significant decrease (p <0.01, Chi Squared) 
in attendance in the oldest age band. ( see Table 2.1). The age range has 
been kept in the original decades from 25 -74 years even though they were 
screened 9 months to one years after their attendance at MONICA 3 
Table 2.1: Attendance by age and sex 
AGE GROUP (yrs) MALE % (n) FEMALE % (n) 
25 -34 93% (128) 87% (132) 
35 -44 82% (153) 85% (169) 
45 -54 96 %. (161) 74% (183) 
55 -64 82% (174) 91 % (172) 
65 -74 74% (181) 69% (188) 
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2.2 Echocardiogram 
Standard two -dimensional, colour and Doppler echocardiography (Acuson 
128) was performed with subjects recumbent at approximately 40 degrees, in 
the left lateral position. ECG electrodes were applied to produce a concurrent 
ECG tracing with a predominant negative deflection. Images were stored on 
videotape and analysed on line. 
2.2.1 Left Ventricular Ejection Fraction 
The left ventricular ejection fraction was obtained using the biplane disc 
summation method (Simpson's Rule) (Schiller et al. 1979) from the apical four 
and two chamber views. The endocardium (defined as the innermost black - 
white interface) was manually traced round using a tracker ball in diastole (the 
onset of the R wave on the ECG) and systole (the smallest left ventricular 
volume), in triplicate, in both the apical two and four chamber views). The 
papillary muscles were considered to be part of the ventricular cavity. Each 
ejection fraction calculated was a mean of three cardiac cycles (excluding 
ectopic, pre or post ectopic beats). Echocardiograms were deemed 
acceptable in terms of quality if 80% or more of the endocardium was visible. 
2.2.2 M -Mode Measurements 
All M -Mode measurements were made on three consecutive cardiac cycles 
(where possible) from the parasternal long axis view. They were not 
performed on ectopic, pre or post ectopic beats. Diastole was defined as 
above and systole as the point at which the furthest anterior motion of the 
posterior wall of the left ventricle occurred. M -Mode echocardiograms were 
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analysed according to the American Society of Echocardiography leading 
edge to leading edge methodology (Sahn et al. 1978). To ensure adequate 
quality control, the criteria of Schieken et al (Schieken et al. 1979) were used 
to determine acceptable technical quality for M -Modes i.e.:(1) the generation 
of a single dominant line representing the interface being imaged, (2) the 
demonstration of continuous interface lines at least 5mm in length at the point 
of measurement, (3) the demonstration of interfaces with the wall motion 
characteristic of the specific cardiac structure being imaged. 
The following M -Mode measurements were made: (1) Left ventricular end 
diastolic dimension (LVEDD), (2) Left ventricular end systolic dimension 
( LVEDD), (3) Interventricular thickness in systole (IVSs) and diastole (IVSd), 
(4) Left ventricular posterior wall thickness in systole (LVPWs) and diastole 
(LVPWd). 
2.2.3 Doppler Echocardiography 
The mitral forward flow was obtained using Pulsed Wave Doppler after 
positioning the callipers between the tips of the mitral valve leaflets in the 
apical 4 chamber view. Aortic forward flow was determined using continuous 
wave Doppler recording in the apical 5 chamber view. Doppler 
measurements were made on five wave forms to minimise respiratory 
influences. For Doppler peak velocity and flow velocity integrals, the spectral 
areas were traced round using the peak velocity correction (Benjamin et al. 
1992) i.e. the outer edge of the spectral envelope. Measurements were made 
from beats demonstrating the following characteristics: (1) highest peak 
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velocity, (2) narrowest spectral dispersion and (3) the most normal contour 
appearance. 
Transmitral Doppler waveforms were considered inadequate if: (1) the angle 
between the Doppler beam and the mitral waveform was >_30 °, (2) the sample 
volume was inadequately positioned, (3) the Doppler signal transmitted was 
too indistinct or (4) there was a tachycardia i.e. a heart rate greater than 100 
bpm 
"A" wave measurements were obviously impossible in the presence of atrial 
fibrillation. 
If mitral incompetence was seen on colour flow, the extent of the 
incompetence was assessed by mapping the extent of the jet into the left 
atrium using pulsed wave Doppler (PW). A semi -quantitative scale was used 
dividing the left atrium into four equal sectors. Mild mitral incompetence (MR) 
was said to be present if the PW jet did not extend more than half way back 
into the left atrium during systole. Moderate MR was defined as the PW jet 
extending to the third quarter of the left atrium and severe MR if the jet could 
be detected in the quarter of the left atrium most distal to the mitral valve. 
Significant mitral incompetence was taken as anything other than mild MR. 
2.2.4 Significant Valvular or Structural Heart Disease 
Echocardiograms were analysed subjectively in real time and deemed to be 
significantly abnormal (and therefore excluded from the derivation of the 
normal range for the left ventricular ejection fraction) if they demonstrated any 
of the following abnormalities: a ventricular or atrial septal defect, hypertrophic 
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obstructive cardiomyopathy (see derived echo measurements), a left 
ventricular aneurysm, cor triatiatum, a pericardial effusion, contained a 
prosthetic valve, had a bicuspid aortic valve, or had any degree of mitral 
(pressure half time >120ms) or aortic stenosis (gradient >20mmg), or greater 
than mild mitral or aortic regurgitation. 
2.2.5 Derived Echocardiogram Measurements 
Fractional Shortening (FS) % = 
LVEDD-LVESD x 100 
LVEDD 
LV Mass (grammes) 
=1.04[(IVSd+LVEDD+LVPWd)3-LVEDD3]-13.6 
This was calculated using the Penn Cube formula (Devereux et al. 1986). LV 
Mass index was computed by dividing the LV mass in grammes by height in 
metres. 
LV Ejection Fraction ( %) 
LV end diastolic volume -LV end systolic volume x100 
LV end diastolic volume 
The LV systolic and diastolic volumes were determined using the Simpson's 
biplane 20 segment disc summation method (Schiller et al. 1979). 
Aortic pressure gradient (mmHg) 
= 4xaortic peak velocity (m /s)2 
Significant aortic stenosis was taken as a gradient >20mmHg. 
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Aortic incompetence as seen by Colour Doppler was deemed to be important 
if it was moderate or severe as measured by the presence of a deceleration 
slope of >2.5m/s2. 
Mitral stenosis was diagnosed if there was a pressure half time of the E wave 
was >120ms. 
Hypertrophic obstructive cardiomyopathy was said to be present if there was 
hypertrophy of the septum disproportionate to that of the posterior wall: the 
ratio of the IVSd:LVPWd being >1.3. 
Mitral valve prolapse was defined as an excursion of a mitral valve leaflet of 
more than 3mm beyond the mitral valve annulus towards the left atrium. 
2.2.6 Intraobserver and Interobserver Variation 
Quantitative echocardiogram analysis was carried out by a single observer 
(myself). A random sample of 10% was reanalysed, blind to the first reading, 
by the same observer for the calculation of the intraobserver variation of 
measurements and a separate 5% random sample analysed by a second 
observer for the determination of the interobserver variation of the 
measurements. 
2.3 Interview and Questionnaire 
All subjects completed a questionnaire giving demographic details, current 
medication, a history of physician diagnosed myocardial infarction, angina, or 
diabetes mellitus, their smoking status (current, never or ex) and answered 
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the Medical Research Council Breathlessness questions (Fletcher et al. 
1959). 
2.4 Blood Pressure 
Blood pressure was taken as a mean of two readings, measured sitting (after 
five minutes rest), in the right arm, using a random zero sphygmomanometer. 
2.5 Body Mass Index 
Subjects were measured, without their shoes and heavy outer garments, 
using a stadiometer on a hard surface. The participant had their back to the 
ruler, the back of the head, back, calves, buttocks and heels were touching 
the upright with the feet together. The top of the external auditory meatus 
was level with the inferior margin of the bony orbit. The triangle on the height 
rule was placed on the head so the hair was pressed flat. Height was then 
recorded to the nearest centimetre. 
Weight was measured using SECA electric scales, which were calibrated with 
a 5Kg weight daily. Subjects were weighed without shoes or heavy outer 
garments and the weight recorded to the nearest 100g. 
Body mass index (BMI) was calculated by dividing the weight in kg by the 
height in metres squared (m)2. 
2.6 Venous Blood Sampling 
2.6.1. Natriuretic Peptide Concentrations 
Venous blood was withdrawn after twenty minutes of supine rest into chilled 
tubes containing EDTA and trasylol (50 iu /ml). Samples were centrifuged at 
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3000rpm for 10 mins at 4 °C and the plasma separated and stored at -20 °C 
for subsequent analysis. Both N terminal atrial natriuretic peptide (N -ANP) 
and brain natriuretic peptide (BNP) concentrations were measured after 
extraction from plasma. The plasma was acidified with an equal volume of 
trifluoroacetic acid (TFA), mixed and centrifuged. The acidified plasma was 
allowed to pass slowly through a Sep -Pak C18 mini column (Waters) which 
had been preconditioned with methanol (5ml), then 1% TFA (5ml) and finally 
1% TFA (2 X 3ml). The column was then washed with 1% TFA(5ml) followed 
by 0.1% TFA (2ml). The eluted peptides were dried by rotatory vacuum and 
redissolved in buffer for assay. Recoveries were 87% and 82% for N -ANP 
and BNP respectively. 
N -ANP was measured, after dilution (1:100) by radioimmunoassay using an 
antibody from Peninsula Laboratories (RAS 9129) raised against the 1 to 30 
N- terminal fragment. This antiserum has no detectable cross reaction with 
either C terminal ANP or BNP and has an IC50 of 18pg /tube in the assay. The 
within -assay and between -assay coefficients of variation (Cvs) for this assay 
were 15% (n =16) and 16% (n =48) respectively (Lang et al. 1993) 
BNP was measured in the extract (1:4) using a radioimmunoassay kit for 
human BNP obtained from Peninsula Laboratories (RIK 9086). This has an 
ICS0 of 20pg /tube. The within -assay and between -assay Cvs were 18% 
(n =16) and (n= 46)15% respectively (Heublein et al. 1989). 
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2.6.2 The Angiotensin Converting Enzyme I/D Polymorphism 
Lymphocytes were isolated from blood and DNA was prepared by standard 
techniques (by F Cambien at INSERM, Paris). The ACE I/D polymorphism 
was detected by polymerase chain reaction amplification (PCR), followed by 
allele specific hybridisation. Each amplification was performed using 500ng of 
DNA in a total volume of 54,I containing 25pmoles of primers (Rigat et al. 
1992): 0.2U Taq polymerase (Euroentec), 20011M dNTP, 1X Taq buffer 
(10mM Tis -HCI pH9, 50mM potassium chloride, 1.5mM magnesium chloride, 
0.2% TironX100 and 0.2mg /m1 bovine serun albumin, 5% DMSO. After 
denaturation at 94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min and a terminal 
72 °C extension for 10 mins, genotyping was performed using allele- specific 
oligonucleotides (ASO)(Ludwig et al. 1993). One fifth of the PCR product was 
denatured in 150µI of 0.5M NaOH and 1.5M NaCI with 1011I of 0.05% 
bromophenol solution and blotted onto nylon membranes (N +ICN), 
neutralised with 0.2XSSC (standard saline citrate:0.15M NaCI and 0.015M 
trisodium citrate). Then the membranes were incubated in buffer (0.9 M 
NaCI, 0.09 M EDTA, 0.1% sodium dodecyl sulphate and 200µg sonicated 
DNA herring sperm) for 1 hour and hybridized at -5 °C for 2 hours with 50 
pmoles of allele- specific probes labelled with phosphorus -32. The 
membranes were washed twice at room temperature in 1XSSC for 5 mins, 
followed by 2 mins in 0.5XSSC at -3 °C. The membranes were dried and 
autoradiography was carried out for 4 -12 hours. 
60 
2.6.3 Serum Cholesterol 
Venous blood was sampled for the measurement of non fasting serum total 
cholesterol, by an enzymatic method (Boehringer). Total serum cholesterol 
was recorded as the average of two measurements (mg /ml). 
2.7 12 Lead Electrocardiogram 
Standard 12 lead ECGs were coded by two observers, for the presence of 
pathological Q waves, left bundle branch block, ST segment depression, T 
wave abnormalities, left ventricular hypertrophy or atrial fibrillation /flutter using 
the Minnesota Coding system (codes; 1.1, 1.2, 1.3, 3.1, 3.3, 3.4, 4.1 -4.4, 5.1- 
5.3, 7.1, 8.31, 8.32) (Prineas et al. 1982). Unresolved discrepancies were 
arbitrated by a third coder. 
2.8 Alcohol Consumption 
This was derived from the self reported questionnaire and expressed in units 
per week. Alcohol consumption beyond the 95th centile was defined as 
excessive. 
2.9 Exercise Test 
2.9.1 Conduct of the Test 
Symptom limited, maximal exercise testing was carried out (on those subjects 
with no contraindication to treadmill stress testing, namely: unstable angina, 
recent myocardial infarction, decompensated chronic heart failure, critical 
aortic stenosis, severe hypertrophic cardiomyopathy, acute systemic illness, 
mechanical instability or a resting systolic blood pressure >220 mmHg or 
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>110 mmHg diastolic) using the Standardised Exponential Exercise Protocol 
(Northridge et al. 1990). A short demonstration was given by the technician 
prior to the test, the subject was then allowed to familiarise themselves with 
walking on the treadmill. All communication with the subject was 
standardised. Before commencing, it was explained that they should 
continue until they could go no longer. Encouragement was given every three 
minutes. A 12 lead ECG was recorded during the last 10 seconds of each 
minute of exercise and at 1, 3 and 5 minutes post exercise. Systolic blood 
pressure was measured every 3 minutes during exercise and immediately on 
stopping the test. Once a subject indicated their desire to stop, they were 
asked if they could manage a bit more, if they could not the test was then 
terminated. The test could also be stopped by the supervising physician 
(myself) if the subjects experienced grade 11111V chest pain, extreme dyspnoea 
or fatigue, leg pain, dizziness or light headedness, a significant arrhythmia 
(sustained ventricular tachycardia, rapid atrial fibrillation or supraventricular 
tachycardia), >3mm of ST segment depression, a fall in systolic blood 
pressure of >20mmHg, the development of a blood pressure >250 /120 mmHg, 
ataxia, ST segment elevation of >1mm in a non -Q wave lead, decreasing 
heart rate or unwillingness on the part of the subject to continue (Froelicher, 
1994). 
Whether the test was subject or doctor limited, the reason for stopping was 
recorded and the duration of exercise noted. 
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2.9.2 Analysis of the Test 
All exercise tests were analysed independently by two coders for the 
presence of ST segment depression. Discrepancies in coding were arbitrated 
by a third coder. The ST segment depression was assessed by measuring it 
in every lead of the resting and peak exercise ECGs using only the first 
codeable beat. If the peak exercise ECG was uncodeable then the first 
recovery ECG was used. The ST measurements were made using the 
Minnesota Coding Method (Prineas et al. 1982) at 80ms past the J point 
(determined using a graticule which allows the identification of the point and 
measurement of the ST segment without moving the line identifying the 
baseline). When two or more leads had the same ST change, the order of 
preference for using a lead was as follows: V5,V6, V4, V2,I,AvL,II,III,AvF,V1. 
The slope of the ST segment was also recorded using the Minnesota coding 
criteria as downward, horizontal or upward sloping. The rhythm at the 
beginning and end of the test was classified by the supervising doctor 
(myself). The analysis was carried out by experienced coders who had 
achieved a satisfactory standard in set tests of ECGs used as quality controls 
at various times during the WHO MONICA project. 
2.10 Ethics 




The Prevalence of Symptomatic and Asymptomatic Left 
Ventricular Systolic Dysfunction in an Urban Population 
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3.1 INTRODUCTION 
Despite the falling trend for other cardiovascular disorders, the incidence and 
prevalence of chronic heart failure (CHF) are predicted to rise substantially 
over the next ten years (Bonneaux et al. 1994). Already, increasing rates of 
hospitalisation for CHF have been reported from Europe and the United 
States (Gillum, 1987, McMurray et al. 1993, Ghali et al. 1990), and it now 
accounts for 1 -2% of all health care expenditure (Costanzo et al. 1995). 
In developed countries CHF is mainly attributable to left ventricular systolic 
dysfunction (although some patients with CHF have diastolic dysfunction). Its 
considerable morbidity and mortality (McKee et al. 1971, Ho et al. 1993b,The 
SOLVD Investigators, 1991) can be significantly improved by appropriate 
treatment (The SOLVD Investigators, 1991, Swedberg et al. 1987). 
Moreover, treatment of asymptomatic left ventricular systolic dysfunction can 
delay or prevent progression to symptomatic left ventricular systolic 
dysfunction and its consequences (The SOLVD Investigators, 1992, Pfeffer 
et al. 1992). 
Despite the increasing importance of CHF and recent therapeutic 
developments, relatively little is known about its epidemiology and less still 
about its probable precursor, asymptomatic left ventricular systolic 
dysfunction. Most existing population surveys have relied upon a clinical 
diagnosis of CHF (McKee et al. 1971, Eriksson et al. 1989a, Schocken et al. 
1992) However, recent work has shown that many symptomatic patients 
thought to have CHF do not have left ventricular systolic dysfunction, or, 
indeed any significant cardiac abnormality (Wheeldon et al. 1993b). In 
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addition, previous population surveys have been unable to identify those with 
asymptomatic left ventricular systolic dysfunction. 
This chapter reports the first large scale epidemiological study, using two 
dimensional echocardiography, of the prevalence of both symptomatic and 
asymptomatic global left ventricular systolic dysfunction in men and women 




This is as described in the methods section. It comprises 1640 individuals 
(response rate 83 %). This present sample is representative of the parent 
cohort in all relevant criteria with the exception that the attendees were more 
affluent and there were fewer smokers. The prevalence of coronary heart 
disease and hypertension was the same as that of the parent cohort. 
3.2.2 Echocardiogram 
Standard 2D echocardiography was performed as described in the methods 
section: the left ventricular ejection fraction (LVEF) was obtained using the 
biplane disc summation method (Simpson's Rule) (Schiller et al. 1979), M- 
Mode parameters that were measured included the left ventricular end 
diastolic dimension (LVEDD) and fractional shortening (FS). 
Quantitative echocardiogram analysis was carried out by a single observer. 
A random sample of 10% was reanalysed, blind to the first reading, by the 
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same observer and a separate 5% random sample analysed by a second 
observer. The intraobserver variation for the LVEF expressed as a median 
percentage error equalled 7 %. The interobserver variation was 10 %. 
3.2.3 Definitions 
Hypertension: a measured blood pressure of >160 mmHg systolic and /or 95 
mmHg diastolic and /or current treatment with antihypertensive medication. 
Ischaemic Heart Disease: the presence of either a self reported doctor 
diagnosis of angina and /or myocardial infarction and /or current use if nitrates 
and /or the presence of a Q wave indicative of previous myocardial infarction 
or major or minor ischaemia on the ECG (Minnesota codes: 6-1,6-2,6-3,6-8,8 - 
3-1,8-3-2,4-1,4-2,4-3,4-4,5-1,5-2,5-3,1-3,7-1,1-1,1-2) 
Left ventricular systolic dysfunction: to derive a "normal range" for LVEF, 
potentially abnormal subjects were defined as those with angina, myocardial 
infarction, hypertension, diabetes, a history of peripheral or cerebrovascular 
disease, those taking cardioactive medication and those with 
echocardiographic evidence of significant valvular heart disease. The 
distribution of LVEF was obtained for the remaining "normal" population. A 
LVEF <_30% was taken as "definite" left ventricular systolic dysfunction - a 
reduction of approximately one -third from the population mean. "Possible" left 
ventricular systolic dysfunction was defined as a LVEF <_35 %. 
Thus symptomatic left ventricular systolic dysfunction, or heart failure, refers 
to left ventricular systolic dysfunction with either the presence of "cardiac 
dyspnoea" from the MRC Breathlessness Questions (dyspnoea on effort, at 
rest or paroxysmal nocturnal dyspnoea in the absence of cough and sputum 
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production for more than three days of the week for three months of the year) 
and /or current therapy with a loop diuretic. Asymptomatic left ventricular 
systolic dysfunction denotes left ventricular systolic dysfunction in the 
absence of cardiac dyspnoea or loop diuretic therapy. 
3.2.4 Statistical Analysis 
Chi squared tests were used to evaluate differences in the proportions of 
individuals with and without left ventricular systolic dysfunction. Continuous 
variables between those in whom an echocardiographic LVEF was obtainable 
versus those in whom it was unobtainable were compared using the Student's 
t test. Linear regression analysis (MINITAB) was used to determine the effect 
of the LVEF on the presence of symptoms (i.e. breathlessness or the 
requirement of a loop diuretic). The other variables included in the model 
were age, smoking, BMI, IHD, and hypertension. 
3.3 RESULTS 
3.3.1 Echocardiogram Acceptability 
A biplane ejection fraction was measurable in 89.5% (1467) of the subjects, 
ranging from 85.6% in men aged 65 -74 to 95.8% in women aged 35 -44. 
(Table 3.1). 
This measurement was fairly uniformly obtainable across the age sex groups 
(although the measurement was statistically significantly more obtainable in 
younger subjects, p= 0.002) when compared to the more commonly used M- 
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Mode parameters of LV function, which were only available in 68.5% of 
subjects (see Table 3.2). The ability to perform M -Mode analysis declined 
with markedly with age (p <0.0001), partly reflecting poorer preservation of the 
parasternal echo window and also deformation of the basal portion of the 
interventricular septum (Table 3.2). 
Due to the greater efficacy of the Biplane Simpson's Rule LVEF in evaluating 
LV function for all ages within our population, as well the evidence that it 
yields the best correlation with other modalities used to assess left ventricular 
ejection fraction such as radionuclide ventriculography and angiography, we 
have used this measurement as our gold standard for LV function (Stamm et 
al 1992). All subsequent analyses of LV function refer to this gold standard. 
Subjects in whom a LVEF could be measured were significantly younger, had 
a lower prevalence of diabetes and hypertension and had lower body mass 
indices. There was also a trend toward them having a lesser prevalence of 
angina (Table 3.3). 
3.3.2 Left Ventricular Ejection Fraction 
LVEF was skewed to the left in the total population in whom an adequate 
echo examination was available (n= 1467), and had a mean value of 46.6% 
(Figure 3.1). LVEF was approximately normally distributed in the "normal" 
population free of cardiovascular disease (Figure 3.2) with a mean value of 
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Table 3.1 
Left Ventricular Ejection Fraction (Simpson's Rule) Obtainability 
Age group (yrs) Male (n) Female (n) . 
25 -34 95.3% (122) 95.4% (126) 
35 -44 88.2% (135) 95.8% (162) 
45 -54 85.7% (138) 86.9% (159) 
55 -64 90.8% (158) 86.6% (149) 
65 -74 85.6% (155) 87.2% (164) 
Table 3.2 
LVEDD and FS Obtainability. 
Age group (yrs) Male % (n) Female (n) 
25 -34 87.0% (111) 93.7% (124) 
35 -44 81.8% (125) 83.6% (141) 
45 -54 60.3% (97) 67.9% (124) 
55-64 62.4% (108) 54.5% (149) 
66 -74 49.7% (90) 46.5% (87.4) 
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Table 3.3 
Comparison of Characteristics of Those in Whom a LVEF 




(n =173) P value 
Age mean (SD) 50.4(14) 54(12) 0.0002 
range 25 -74 25 -74 
Sex males 48.1% 51.4% 0.42 
Angina 10.6% 15.6% 0.05 
Self reported MI 5.1% 7.2% 0.26 
Diabetes 2.5% 6.4% 0.004 
Hypertension 38.6% 50.3% 0.004 
SBP(mmHg) mean(SD) 132(23) 137(23) 0.67 
DBP(mmHg) mean(SD) 78(12) 80(12) 0.86 
Body Mass Index 
(kg /m2) mean(SD) 25.9(4.3) 29.4(7.6) <0.0001 






























































































































































































































































































































































































































































47.3% (standard deviation 6.5, range 26 -70). Two standard deviations below 
the mean was 34% and the 5th centile value was 35 %. The mean left 
ventricular ejection fraction was slightly less in "normal" men (46.6% SD 6.6) 
than in women (48% SD 6.4 %) (p= 0.02). 
3.3.3. Prevalence of Left Ventricular Systolic Dysfunction (Figure 3.3) 
`Definite' (left ventricular ejection fraction <_30 %) 
This was present in 2.9% (n =43) of the population with a marked difference in 
the prevalence between men (4 %) and women (2 %) (p <0.001). Symptomatic 
left ventricular systolic dysfunction occurred in 1.4% of subjects while 1.5% 
were asymptomatic. 
The prevalence of definite left ventricular systolic dysfunction increased with 
age and was higher in men than in women for each age group (Figure 3.3), 
ranging from 0.0% in men and women aged 25 -34 yrs to 6.4% in men over 
age 65 years (Figure 3.3). 
`Possible' (left ventricular ejection fraction <_35 %) (Figure 3.4) 
The prevalence of an ejection fraction of <_35% was higher in males and 
increased with age. Overall 7.7% (113) of subjects had an ejection fraction 
s35 %, of whom 77% were asymptomatic (Figure 3.4). 
The proportion of symptomatic subjects does increase as the ejection fraction 
gets lower (see Table 3.4). In the linear regression model the presence of left 
ventricular systolic dysfunction was independently associated with the 

































































































































































































































































































































































































































































































































































Symptomatic and Asymptomatic Left Ventricular Systolic Dysfunction 









<_20 8 4 12 67% 
21 -25 3 4 7 43% 
26 -30 9 13 22 41% 
31 -35 6 61 67 7% 
>_36 146 1168 1314 11% 
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with breathlessness or the need for loop diuretic therapy were increasing BMI 
(p <0.001), the presence of IHD (p <0.001) and hypertension (p= 0.03). Current 
smoking (p =0.97) and age (0.054) were not significant in the model. One 
hundred percent of those with symptomatic left ventricular systolic dysfunction 
and 95% of those with asymptomatic left ventricular systolic dysfunction had 
some evidence of IHD or hypertension. Using a cut -point for left ventricular 
ejection fraction of <35 %, 75% have IHD or hypertension. 
3.3.4 Treatment and Left Ventricular Systolic Dysfunction 
Of symptomatic subjects with definite left ventricular systolic dysfunction, 65% 
(11) were receiving treatment with a diuretic and /or an angiotensin converting 
enzyme inhibitor and /or digoxin. 
In subjects with a LVEF530% (irrespective of their symptom status): 18% 
(7/39) were currently taking an ACE inhibitor, 31% (4/13) of those with 
symptomatic definite left ventricular systolic dysfunction and 11.5% (3/26) with 
asymptomatic left ventricular systolic dysfunction were on ACE inhibitor 
therapy. 
5.4 DISCUSSION 
This is the first study to my knowledge to report the prevalence of both 
symptomatic and asymptomatic left ventricular systolic dysfunction in a 
geographical population of men and women using an objective measure of 
left ventricular function. 
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The study demonstrates that a low ejection fraction is common, with 2.9% of 
the population having definite left ventricular systolic dysfunction, of which 
half is asymptomatic. 
Given that left ventricular ejection fraction is normally distributed, the first 
question raised by this work is "What is normal left ventricular function ? ". The 
decision to choose ___30% to indicate `definite' left ventricular systolic 
dysfunction is justified by 100 % of those with symptomatic left ventricular 
systolic dysfunction and 95% of those with asymptomatic left ventricular 
systolic dysfunction having a plausible underlying cause, i.e. IHD or 
hypertension. However, a 2.9% prevalence of definite left ventricular systolic 
dysfunction should be regarded as a minimum. Using a cut -point for left 
ventricular ejection fraction of <_35 %, the prevalence of left ventricular systolic 
dysfunction increases to 7.7 %, and, of these subjects, 75% have IHD or 
hypertension. However, 35 %, which is on the borderline of statistical 
normality for this measurement, would include biologically normal subjects. 
Therefore, in order to define a minimum prevalence which also takes account 
of the variability of echocardiographic left ventricular ejection fraction, I have 
opted for a value where there can be little doubt about its clinical significance. 
The true prevalence of left ventricular systolic dysfunction will, however, lie 
somewhere between 2.9% and 7.7 %. 
It is also evident from the population sample that the amount of left ventricular 
systolic dysfunction may have been underestimated as attendees were more 
affluent and less likely to be smokers, and those in whom a left ventricular 
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ejection fraction could be measured were younger, had a lower prevalence of 
hypertension and a displayed a trend towards less ischaemic heart disease. 
Using a definition of CHF as "symptomatic left ventricular systolic dysfunction" 
(Task Force on Heart Failure of the European Society of Cardiology 1995) 
facilitates comparison with other studies. In this population, 1.4% had 
symptomatic left ventricular systolic dysfunction. "The study of men born in 
1913" (Eriksson et al. 1989) which was limited to men, with CHF diagnosed 
on symptoms and signs, quoted "manifest heart failure" as occurring in 2.4% 
at 54 years, 4.3% at 60 years and 13% at 67 years. The results presented 
here yielded slightly lower prevalence rates for symptomatic left ventricular 
systolic dysfunction of 1.5% in men aged 45 -54, 2.5% in those aged 55 -64 
and 3.2% in those aged 65 -74. This may be due to the power of the present 
study in distinguishing subjects, diagnosed clinically, as having CHF who 
have normal systolic function. It should also be borne in mind that this cut off 
value for left ventricular systolic dysfunction is a strict one and gives a 
minimum estimate. 
The prevalence of symptomatic definite left ventricular systolic dysfunction is 
close to that of the recent NHANES Survey (Schocken et al. 1992) quoting 
2% for the general US population and to that in a recent community study 
from a UK city similar to Glasgow (Mair et al. 1996). These rates are higher 
than previously reported in the Framingham study (McKee et al. 1971) where 
more advanced stages of the disease may have been detected due to stricter 
diagnostic criteria. The Framingham Study also began in 1949 and the 
prevalence of CHF is rising (Gillum, 1987, McMurray et al. 1993, Ghali et al. 
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1990), which may partly explain the higher prevalence. Alternatively, North 
Glasgow is an area with a high prevalence of IHD, and is, therefore, likely to 
have more CHF. These results confirm that CHF is significantly more common 
in men than women (McKee et al. 1971). The prevalence reported is also 
greater than that detected in studies based on prescription data which clearly 
pick up a more advanced stage of the disease after it has crossed the 
threshold for therapeutic intervention (Gibson et al. 1966, Parameshwar et al. 
1992b, Clarke et al. 1995) 
Perhaps the most important novel finding of this work is that asymptomatic left 
ventricular systolic dysfunction is at least as common as CHF. The 
Framingham Group found a reduced fractional shortening in 5.2% of men and 
1.9% of women from their "Offspring Cohort" (Vasan et al. 1997a). 
Comparisons are difficult as no assessment of global LV function using a 
biplane method was carried out in that study. In this study 2.7% of 
asymptomatic men and 0.6% of asymptomatic women had definite left 
ventricular systolic dysfunction. Nevertheless, it should be reiterated that this 
is a minimum prevalence since 8.9% of asymptomatic males and 4.2% of 
asymptomatic females had an ejection fraction __35 %. Gardin et al, have also 
published work on subjects over 65 years, using a subjective assessment of 
left ventricular function, and found it to be reduced in 6.8% of asymptomatic 
men and 1.8% of women (Gardin et al. 1995). The present study's figures 
are similar with 4.3% and 2% of asymptomatic men and women, respectively, 
having definite evidence of left ventricular systolic dysfunction. However if we 
were to look at those with a left ventricular ejection fraction <_35 %, this study 
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has much higher estimates with 14.6% of asymptomatic men and 8.9% of 
asymptomatic women over 65 years having an ejection fraction below this 
level. 
Interestingly, the proportion of left ventricular systolic dysfunction which is 
asymptomatic is significantly greater in the younger age groups. One 
explanation is that asymptomatic left ventricular systolic dysfunction is, 
indeed, a latent precursor phase which progresses to CHF with increasing 
age due to intrinsic progress of left ventricular systolic dysfunction or to further 
cardiovascular events. It is also interesting to note that the proportion of left 
ventricular systolic dysfunction that is symptomatic increases as the ejection 
fraction falls. This also lends weight to the asymptomatic phase being a 
transitory harbinger of more serious disease. 
Whether the asymptomatic left ventricular systolic dysfunction detected in this 
work will progress to CHF is as yet unknown but will be resolved at 
subsequent follow up. That some subsets with asymptomatic left ventricular 
systolic dysfunction will progress is supported by work indicating a higher 
odds ratio for the development of cardiovascular disease for those with 
subclinical LV dilation (Lauer et al. 1992) in the Framingham Offspring Cohort 
and in those with asymptomatic left ventricular systolic dysfunction in the 
SOLVD Prevention Trial (The SOLVD Investigators, 1992). Additionally, the 
increased hazard ratio for the development of CHF obtained in the 11 year 
follow up of subjects with subclinical left ventricular dilation in the Framingham 
Offspring Cohort (Vasan et al. 1997a) suggests that the asymptomatic left 
ventricular systolic dysfunction we have uncovered will also progress to CHF. 
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Echocardiography proved a useful epidemiological tool in this work; the left 
ventricular ejection fraction according to Simpson's Rule was readily obtained 
in nearly ninety percent of our subjects, making it more useful than M -Mode 
(only adequately obtained in 68.5 %). 
However, comparisons between studies using echocardiography pose some 
difficulties because differences in hardware, software and quantitative 
analysis techniques will cause unquantifiable differences. 
As just over half of the left ventricular systolic dysfunction identified in this 
study was asymptomatic and the symptomatic left ventricular systolic 
dysfunction was undertreated, and since progression of asymptomatic left 
ventricular systolic dysfunction to CHF can be ameliorated by the use of ACE 
inhibitors in patients with cardiac disease, (The SOLVD Investigators, 1992) 
these findings have important implications both for prevention and screening 
for left ventricular systolic dysfunction. 
This chapter has demonstrated that left ventricular systolic dysfunction is 
more common than some diseases such as breast and cervical cancer (with a 
similar prognosis) for which considerable resources for screening are 
deployed. Ideally requirements for health care should be estimated using 
disease prevalence figures calculated from accurate, objective techniques 
and applying them to future estimations of an ageing population. If the 
current patterns of health care persist for CHF then the implication is that 
substantially more resources will be required. Nearly twenty per cent of 
patients with CHF are hospitalised at least once per annum (Bourassa et al. 
1993). In- patient treatment of CHF costs the NHS £214.25 million per annum 
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(59.5% of the total direct costs to the NHS for CHF) (McMurray and Davie, 
1996). 
Policy makers need to devise ways of reducing the potentially increasing 
burden of left ventricular systolic dysfunction on resources. Effective drug 
therapy for symptomatic left ventricular systolic dysfunction reduces mortality, 
hospitalisation rates and length of stay (The SOLVD Investigators, 1991). 
Optimising the use of appropriate drug therapy should be a priority for health 
care purchasers considering that only 31% of those with symptomatic left 
ventricular systolic dysfunction were on desirable CHF therapy. In addition, 
the use of ACE inhibitors has been shown to be cost effective. Also alarming, 
but perhaps less surprising, is the finding that only 11.5% of subjects with 
asymptomatic left ventricular systolic dysfunction were on effective treatment. 
This chapter, by revealing its magnitude, has highlighted the need to focus on 
case finding for symptomatic, and screening for asymptomatic left ventricular 








When the Framingham Heart Study reported its findings, over a quarter of a 
century ago, three quarters of all the CHF they identified was attributed to 
hypertension (McKee et aI. 1971). Similarly in the "Study of the men born in 
1913 ", hypertension was implicated as a significant aetiological factor in over 
half the cases they discovered (Eriksson et al. 1989). More recently, data 
from the heart failure treatment trials has indicated that ischaemic heart 
disease is now the principal cause of CHF; being responsible for 
approximately three quarters of cases (The SOLVD Investigators. 1991). 
Since the main population -based studies on CHF reported, there appears to 
have been a shift in the main aetiology of CHF, from hypertension to 
ischaemia. This observation, coupled with the fact that there are no 
epidemiological data on the determinants of left ventricular systolic 
dysfunction in the general population, showed a need to update this 
information. This chapter, therefore, examines the aetiological correlates of 
left ventricular systolic dysfunction in a random sample of men and women 
aged 25 -74 in a geographical population with a high standardised mortality 
ratio for coronary heart disease. 
4.2 METHODS 
4.2.1 Population 
For this section of the study the population is as described in the methods 
and consists of the 1467 subjects who had a biplane ejection fraction 
available. They also had questionnaire data regarding their history of 
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myocardial infarction, angina and diabetes, and their current drug treatment, a 
measurable systolic and diastolic blood pressure and a 12 lead ECG, which 
was Minnesota Coded. 
4.2.2 Definitions 
Angina: a history of physician diagnosed angina and /or the current use of 
nitrate drugs. 
Myocardial infarction (Ml): a history of doctor diagnosed MI or the presence 
of a pathological Q wave on the ECG. 
ECG Ischaemia: Any of the following Minnesota Codes including (1) Minor 
Ischaemia (6- 1,6 -2, 6 -3, 6 -8, 8 -3 -1, 8 -3 -2) (2) Major Ischaemia (4 -1, 4 -2, 4 -3, 
4 -4, 5 -1, 5 -2, 5 -3, 1 -3 and 7 -1) and (3) MI (1 -1 or 1 -2). 
Ischaemic Heart Disease (IHD): the presence of angina and /or MI and /or 
ECG ischaemia. 
ECG abnormal: Any code including ECG ischaemia plus left ventricular 
hypertrophy (code 3 -1 and 3 -3) and /or left bundle branch block (7- codes). 
Left Ventricular Hypertrophy (LVH): refers to ECG criteria for LVH 
(Minnesota codes 3 -1 and /or 3 -3). 
Hypertension: a measured blood pressure of >160 mmHg systolic and /or 95 
mmHg diastolic and /or current treatment with antihypertensive medication. 
Diabetes mellitus: a history of diabetes and /or current treatment with an oral 
hypoglycaemic agent or insulin. 
Definite left ventricular systolic dysfunction: A left ventricular ejection 
fraction <30 %. 
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Possible left ventricular systolic dysfunction: A left ventricular ejection 
fraction <_35 %. 
Regarding left ventricular systolic dysfunction, symptomatic refers to the 
presence of "cardiac dyspnoea" and /or current therapy with a loop diuretic 
and asymptomatic, the absence of cardiac dyspnoea or loop diuretic therapy. 
(see Methods for fuller explanations, where the definitions of alcohol excess 
and valvular abnormalities are also given). 
4.2.3 Statistical Analysis 
Chi Square or Fisher's Exact tests (where appropriate) were used to evaluate 
differences in the proportions of individuals with risk factors between the 
subgroups of the study population. Odds ratios were estimated using linear 
logistic regression analysis. A p value of <0.05 has been considered 
significant. 
4.3 RESULTS 
4.3.1 Correlates of Left ventricular systolic dysfunction (Table 4.1) 
lschaemic Heart Disease 
Table 4.1 shows the prevalence of various manifestations of ischaemic heart 
disease (IHD) in symptomatic and asymptomatic individuals with definite left 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































asymptomatic subjects with ejection fractions >30 %. Some evidence of IHD 
(i.e. a history of angina, myocardial infarction or electrocardiographic 
evidence of ischaemia or infarction: Q waves, left bundle branch block or 
ST/T wave change) was present in 95% of those with symptomatic left 
ventricular systolic dysfunction and 71% of those with asymptomatic left 
ventricular systolic dysfunction (p= 0.04). Fifty percent of those with 
symptomatic left ventricular systolic dysfunction reported a prior myocardial 
infarction and 62% had angina (self -reported or current use of nitrates). Of 
those with asymptomatic left ventricular systolic dysfunction, only 14% had a 
history of myocardial infarction. However, 43% of them had a history of 
angina (p =0.01 for prior myocardial infarction, p =0.02 for angina - 
symptomatic left ventricular systolic dysfunction versus asymptomatic left 
ventricular systolic dysfunction). 
IHD unaccompanied by hypertension occurred in one third of those with 
symptomatic left ventricular systolic dysfunction versus 17% of symptomatic 
individuals with ejection fractions >30% (p <0.001) and also in one third of 
those with asymptomatic left ventricular systolic dysfunction compared to 11 
of asymptomatic subjects with ejection fractions >30% (p <0.001). 
In subjects with a history or electrocardiographic evidence of myocardial 
infarction, 21% had an ejection fraction <_35% and in 15 %, it was <30 %. Of 
those with angina, 11% had an ejection fraction <_35% and 7% had definite 
left ventricular systolic dysfunction. 
In a univariate analysis, a history of myocardial infarction was associated with 
an odds ratio of 10.8 (95% CI: 5.4, 21.5:p <0.001) for left ventricular systolic 
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dysfunction, angina resulted in an odds ratio of 10.7 ( 95% Cl: 5.1, 20.1: 
p <0.0001) and electrocardiographic evidence of ischaemia or infarction gave 
an odds ratio of 10.4 (95% Cl: 5.5,20.0: p <0.001) for left ventricular systolic 
dysfunction. 
Seventy seven percent of those with symptomatic left ventricular systolic 
dysfunction and 60% of those with asymptomatic left ventricular systolic 
dysfunction had an electrocardiogram abnormality (defined as: Q wave, left 
bundle branch block, ST/T change, left ventricular hypertrophy, atrial 
fibrillation /flutter) compared to 8% (symptomatic) and 18% (asymptomatic) of 
those with normal left ventricular function (p <0.001) 
Hypertension 
Table 4.1 also gives the prevalence of hypertension in subjects with 
symptomatic left ventricular systolic dysfunction and asymptomatic left 
ventricular systolic dysfunction compared to symptomatic and asymptomatic 
individuals with a left ventricular ejection fraction >30 %. Some evidence of 
hypertension (history, measured or treated) was found in 68% of those with 
symptomatic left ventricular systolic dysfunction compared with 51% of 
symptomatic subjects without left ventricular systolic dysfunction. Those with 
asymptomatic left ventricular systolic dysfunction had a prevalence of 
hypertension of 52% compared to 17% in asymptomatic subjects with normal 
left ventricular function (p <0.001). 
In the univariate analysis the presence of hypertension was associated with 
an odds ratio of 5.2 for left ventricular systolic dysfunction (95% Cl: 2.8, 9.7: 
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p <0.001). Evidence of left ventricular hypertrophy on the electrocardiogram 
was more common in those with left ventricular systolic dysfunction but not 
significantly so: odds ratio 2.4 (95% CI: 1.0, 5.9: p= 0.08). 
The presence of hypertension and IHD are individually associated with an 
increased risk of left ventricular systolic dysfunction in both symptomatic and 
asymptomatic subjects. When considered jointly in a logistic regression 
analysis, both were predictive of left ventricular systolic dysfunction, 
conditional odds ratios (95% CI) were 14.3(6.1, 33.4) and 2.5(1.3, 4.8) for IHD 
and hypertension respectively. These calculations were carried out for 
symptomatic and asymptomatic subjects together so that adequate numbers 
were available for the analysis. 
In a more detailed multivariate stepwise logistic regression analysis the 
independent useful predictors of left ventricular systolic dysfunction (odds 
ratios [95% CI] were angina (5.1[2.6,33.4D, electrocardiographic evidence of 
ischaemia or infarction (5.9 [2.9, 12.0]), hypertension (3.0[1.5,5.9]) and male 
sex (2.1[1.1,4.3]). 
In subjects with left ventricular ejection fractions <_35 %, 75% had evidence of 
IHD and /or hypertension 
Hypertension: The Effect of Different Degrees of High Blood Pressure. 
Table 4.2 depicts the prevalence of left ventricular systolic dysfunction, and 
mean LVEF according to the severity of hypertension The blood pressure 





















































































































































































































































































































































































































































































































































































































diastolic, Stage 2 a systolic BP >140 and < =159 and or a diastolic BP of >90 
mmHg and or < =94 mmHg, Stage 3 denotes a systolic blood pressure of 
>_160 mmHg and /or a diastolic of >_95 mmHg (these stages are irrespective of 
whether the subject was taking antihypertensive drugs as there was no 
significant difference either in the mean LVEF or the proportion with left 
ventricular systolic dysfunction between those within each stage whether they 
taking or not taking antihypertensive medication; see Table 4.3). The odds 
ratio (95% confidence intervals in parentheses) for a blood pressure of >_140 
and _ <159 mmHg systolic and /or >_90 mmHG and 594 mmHg diastolic being 
associated with left ventricular systolic dysfunction was 2.2 (0.9, 5.2) where 
as this increased to 6.7 when the blood pressure was >_160 mmHg systolic 
and /or >_95 mmHG diastolic (p =0.004 Chi Square). 
Diabetes mellitus 
The prevalence of left ventricular systolic dysfunction was highest in diabetics: 
in whom 29% (14/48) had a LVEF <_35% and 17 %(8/48) <_30%. Three - 
quarters of definite left ventricular systolic dysfunction in diabetics was 
attributable to IHD (6/8 with evidence of a previous myocardial infarction, in 
whom 3/6 had coexisting hypertension), the remaining quarter (2/8) were 
hypertensive without evidence of IHD. 
Other causes of left ventricular systolic dysfunction 
Significant valvular heart disease on the echocardiogram and alcohol 
consumption beyond the 95'h centile value for the population studied were not 
more prevalent in those with left ventricular systolic dysfunction. 
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Table 4.3: The Degree of Hypertension and the Prevalence of Left 
Ventricular Systolic Dysfunction 
Stase Prevalence of LVSD % n Mean LVEF SD Number 
1 1.2% (11) 47.1 (7.4) 855 
la 4.7% (2) 46.7 (9.4) 56 
2 2.1% (6) 46.0 (7.5) 247 
2a 7.0% (3) 44.9 (8.9) 45 
3 7.6% (18) 44.9 (10.2) 186 
3a 7.0% (3) 47.6 (9.1) 52 
Legend to Table 4.3: LVSD represents left ventricular systolic dysfunction. 
The stages are as for Table 2, except that the presence of an a denotes the 
presence of antihypertensive medication. The number in parenthesis is the 
absolute number of subjects with that risk factor. 
The differences between the mean LVEF values between stages 1 and 1 a 
(p =1), 2 and 2a (p =1), and 3 and 3a (p =0.5) failed to achieve statistical 
significance (Student's t tests). Similarly, the proportions with LVSD between 
stages 1 and 1 a (p= 0.16), 2 and 2a (p= 0.13), 3 and 3a (p =0.38) were not 
significant (Chi- Squared analysis.) 
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4.4 DISCUSSION 
The first point this chapter demonstrates is that both ischaemic heart disease 
and hypertension were extremely prevalent in this population and often co- 
existed. Determining the actual aetiology of the left ventricular systolic 
dysfunction identified in this study is not possible due its design as a cross - 
sectional survey. Sorting out the relative importance of hypertension and IHD 
in the aetiology of left ventricular systolic dysfunction, in general, is complex 
as hypertension is a risk factor for coronary artery disease. In addition, blood 
pressure may fall once systolic dysfunction and CHF ensue, and so a 
measured blood pressure at a screening visit may mask a subject's 
hypertensive past. Also of relevance is the fact that medication for CHF and 
left ventricular systolic dysfunction also lowers blood pressure. However, 
despite these limitations, this work does shed light on the relative 
contributions of these two important risk factors for left ventricular systolic 
dysfunction in an urban population in the 1990s. 
The aetiological factor conferring the greatest odds ratio for left ventricular 
systolic dysfunction in this study was IHD which was found in 83% of subjects 
with left ventricular systolic dysfunction. This contrasts with earlier 
epidemiological work in CHF which implicated IHD as the sole precursor of 
CHF in only 10% of CHF subjects and IHD accompanied by hypertension in 
39% of chronic heart failure (McKee et al. 1971). In this study the 
combination of hypertension and IHD was a powerful predictor of left 
ventricular systolic dysfunction, being encountered in 50% of those with left 
ventricular systolic dysfunction (62% in symptomatic left ventricular systolic 
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dysfunction and 38% of asymptomatic left ventricular systolic dysfunction). 
However, hypertension alone, was not more prevalent in subjects with (10 %) 
or without (13 %) left ventricular systolic dysfunction. In contrast, hypertension 
accounted for 75% of the CHF detected in the Framingham study (McKee et 
al. 1971); it was also the most important independent predictor for the 
development of CHF in the Gothenburg Study (Eriksson et al. 1989). The 
results presented here confirm those of others (Ho et al. 1993b,Teerlink et al. 
1991) and are likely to reflect a temporal change in the aetiology of CHF, 
possibly because hypertension has become more readily detected and better 
treated. 
Some recent data from the Framingham Study dispute the more generally 
held view of IHD being the major cause of CHF (Levy et al. 1996) and still 
implicate hypertension as the predominant CHF risk factor. However in that 
publication the definition of hypertension has changed from a blood pressure 
>160/90 in earlier work to >140/90 in the most recent analysis. As population 
attributable risk is dependent on the prevalence of the risk factor it is hardly 
surprising that hypertension is playing such a prominent part when the blood 
pressure cut -off is reduced to >140/90. In a similar manner to the 
Framingham paper, this work also shows a dose effect of the degree of 
hypertension and left ventricular systolic dysfunction. Although the odds ratio 
for a blood pressure in the range of 140 -159 mmHg systolic and /or 90 -94 
mmHg diastolic was increased, this was not significant until the blood 
pressure was >_160 mmHg systolic and /or 95 mmHg diastolic. This is not to 
say that hypertension should not be regarded as present once a blood 
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pressure of >140/90 mmHg is reached, but rather in the context of 
epidemiological studies where blood pressure is being measured at only one 
visit, the cut -off. of >140/90 mmHg may overestimate the prevalence of 
hypertension. 
The overriding contribution of IHD to left ventricular systolic dysfunction in this 
study is suggested by the increase in the prevalence of left ventricular systolic 
dysfunction in the fifth decade for men and the seventh for women. This 
mirrors the age related increase in prevalence of IHD in this population 
(Tunstall -Pedoe et al. 1994). 
The finding that hypertension and all manifestations of ischaemia become 
more prevalent in those with symptomatic left ventricular systolic dysfunction 
compared to asymptomatic left ventricular systolic dysfunction lends support 
to the theory that further cardiovascular events might be contributing to the 
progression of left ventricular systolic dysfunction to CHF. 
As the predominant determinants of left ventricular systolic dysfunction were 
IHD and concomitant IHD and hypertension, the need for aggressive primary 
and secondary prevention of IHD is underscored. Rigorous management of 
hypertension is important - there is good evidence that treatment of 
hypertension, with angiotensin converting enzyme inhibitors, in those with left 
ventricular systolic dysfunction, reduces mortality and morbidity (Kostis, 
1995). 
Returning to an earlier point made in Chapter 2, the magnitude of the 
prevalence of both symptomatic and asymptomatic left ventricular systolic 
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dysfunction demonstrated in this study seriously raises the issue of case - 
finding for symptomatic and screening for asymptomatic left ventricular 
systolic dysfunction. The work in this chapter confirms that the majority of 
those with asymptomatic left ventricular systolic dysfunction have evidence of 
IHD or hypertension, and therefore, the likelihood is that they would benefit in 
terms of mortality and morbidity from angiotensin converting enzyme 
inhibition. The data shown here also suggest that widespread population 
screening by echocardiography may be unnecessary since 93% of those with 
left ventricular systolic dysfunction are recognisable clinically. Identification of 
high risk target groups (those with angina, myocardial infarction, hypertension 
and diabetes) for further evaluation echocardiographically would be the 
strategy of choice. Thus, resources should be targeted at these groups to 
maximise the accurate detection of left ventricular systolic dysfunction leading 




The Effect of Left Ventricular Systolic Dysfunction on Effort 
Capacity in an Urban Population 
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5.1 INTRODUCTION 
As the cardinal symptoms of CHF occur, at least initially, on exertion, 
exercise testing would be expected to be useful in its evaluation. Indeed, the 
response to maximal stress testing provides a means of grading disability and 
estimating cardiopulmonary reserve in CHF (Zelis et al. 1990). Peak oxygen 
consumption and exercise duration are reduced, not only in subjects with 
symptomatic, but also in those with asymptomatic left ventricular systolic 
dysfunction (LeJemtel et al. 1994). Many studies have shown, in patient 
groups with symptomatic left ventricular systolic dysfunction, that resting 
echocardiographic measures of left ventricular function correlate poorly with 
peak oxygen consumption and exercise duration (Franciosa et al. 1981), 
nevertheless, both are powerful independent predictors of prognosis in 
symptomatic left ventricular systolic dysfunction (Cohn et al. 1993) and can be 
used to estimate the severity of CHF. To date there are no population studies 
on left ventricular systolic dysfunction, which have also incorporated maximal 
exercise testing. This chapter reports the first epidemiological work to study 
the effect of left ventricular systolic dysfunction on effort capacity in a random 
sample from the general population of both men and women aged 25 -74. 
5.2 METHODS 
5.2.1 Population 
This is as described in Chapter 2 and relates to the subjects who had a LVEF 
(Biplane Simpson's Rule), questionnaire data, a 12 lead ECG and who 
completed a maximal exercise test. 
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The definitions of left ventricular systolic dysfunction, symptomatic, 
asymptomatic, ischaemic heart disease, hypertension and ECG abnormalities 
are identical to those used in Chapter 3. 
The LVEF has been split further into four categories for part of the analysis. 
These are 1; LVEF >40 %, 2; LVEF 36 -40 %, 3; LVEF 31 -35 %, 4; LVEF <_30 %. 
Significant ischaemia on exercise testing has been defined as depression of 
the ST segment of >_1 mm at any point during the test or in the recovery 
phase. That ST depression had to be of a horizontal or downward sloping 
nature. 
5.2.2 Statistics 
Exercise times are presented as means ±SDs. Differences between the 
means of those with and without left ventricular systolic dysfunction were 
compared using the Student's t test. The results for the categories 
(asymptomatic left ventricular systolic dysfunction, symptomatic left 
ventricular systolic dysfunction and no left ventricular systolic dysfunction) and 
LVEF categories 1 -4 were tested using analysis of variance (ANOVA). A 
multivariate regression model was used to determine the independent 
predictors of effort capacity (treated as the dependent variable). P values 
<0.05 are considered to be significant. 
5.3 RESULTS 
5.3.1 Characteristics of the Population 
1281 (78% of the screened population) subjects completed a maximal 
exercise test. Their baseline characteristics are shown in Table 5.1. 
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Table 5.1: Characteristics of the Population (Aged 25 -74) 
Which Underwent Exercise Testing 
Age 
Sex 
Evidence of IHD 
mean 49.3 (SD14) 
male 47.8% (613) 
19.7% (252) 
Evidence of Ml 5.6% (69) 
History of angina 8% (103) 
ECG ischaemia 14.4% (181) 
ECG abnormal 18.4% (236) 
Breathless 7.9% (98) 
Hypertension 21% (266) 
Diabetes 1.6 %(20) 
Left ventricular systolic dysfunction (LVSD) 2.2 %(28) 
Asymptomatic LVSD 57.5% (15)* 
Symptomatic LVSD 42.3% (11)* 
Legend to Table 5.1: IHD (Ischaemic Heart Disease) refers to either a history of angina or 
treatment with nitrates or a history of myocardial infarction (MI) or ECG evidence of q waves, 
left bundle branch block (LBBB) or a significant ST/T segment abnormality. Evidence of MI is 
defined as a history of MI or the presence of pathological Q waves on the ECG. ECG 
ischaemia is the presence of a pathological Q wave, LBBB or a significant ST/T segment 
abnormality. An abnormal ECG is defined as those abnormalities constituting ECG ischaemia 
and/or the presence of voltage criteria for left ventricular hypertrophy and /or atrial 
fibrillation /flutter. Breathlessness refers to cardiac dyspnoea according to the MRC 
Breathlessness Questions (in the absence of cough and /or sputum production for more than 3 
days of the week for 3 months of the year). Hypertension is a measured blood pressure of 
>160mmHg systolic and /or 95mmHg diastolic and or current treatment with an 
antihypertensive. Diabetes is defined as a history of physician diagnosed diabetes and /or 
treatment with an oral hypoglycaemic agent and /or insulin. LVSD is a LVEF <_30 %. Treated 
LVSD refers to the prescription of a loop diuretic drug. The figures quoted are percentages 
With the numbers in parentheses, except for age which is followed by the standard deviation 
in 
brackets. *Two subjects had not completed the MRC Breathlessness Questionnaire and could 
not be assigned as symptomatic /asymptomatic. 
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5.3.2 Effort Capacity in the Population 
The frequency distribution histograms for exercise duration in men and 
women are depicted in Figures 5.1 and 5.2, respectively. Effort capacity is 
approximately normally distributed with a tail to the left. The mean exercise 
durations were 736 secs ±163 (SD) for men and 648 ±154 for women. 
5.3.3 Effort Capacity and Left Ventricular Ejection Fraction 
Figures 5.3 and 5.4 show plots of exercise duration and LVEF in men and 
women respectively. It can be seen that any relationship between LVEF and 
exercise capacity is most marked in those whose ejection fractions are s30 %. 
This is seen more strikingly in Figures 5.5 and 5.6 where LVEF is divided into 
the categories shown. For both men and women the mean exercise duration 
is only significantly reduced once the left ventricular ejection fraction is <_30 %. 
5.3.4 Effort Capacity and Left Ventricular Systolic Dysfunction 
Table 5.2 gives the exercise times for men and women with and without left 
ventricular systolic dysfunction. In the univariate analysis, a LVEF _30% was 
associated with a significant reduction in the average exercise duration of 134 
secs for men (p= 0.0001) and 294 secs for women (p= 0.001). Although the 
mean effort capacity for men and women was less in subjects with 
asymptomatic left ventricular systolic dysfunction, it was not statistically 
significant compared to those without systolic dysfunction (regardless of 
symptoms). When those with asymptomatic left ventricular systolic 
dysfunction were compared with asymptomatic subjects with a LVEF >30 %, 
the result was significant for men at p =0.02 but still failed to achieve statistical 
significance in women (p= 0.15). 
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Figure 5.1. 
Effort Capacity in Men aged 25-74 
150 - 
0 
i i i i i i i i 
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Exercise Tire (secs) 
Legend to Fig. 5.1 
Frequency distribution histogram for the 613 men undergoing exercise 
testing. The mean exercise time (secs) was 736, median, 766, 
standard deviation 163 and range 71 to 1094. 
Figure 5.2. 
Exercise Duration in FerrelesAged 
25-74 
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T I 1 
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Legend to Fig. 5.2 
Frequency distribution histogram for the 668 women undergoing 
exercise testing. The mean exercise time (secs) was 648, median, 
670, standard deviation 154 and range 67 to 1000. 
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Figure 5.3 
LVEF and Effort Capacity in Men aged 
25 -74 
Legend to Fig. 5.3 
Exercise duration is expressed in seconds and plotted against 
LVEF ( %) for men. 
Figure 5.4 
LVEF and Effort Capacity in Women Aged 
25-74 
Legend to Fig. 5.4 
Exercise duration is expressed in seconds and plotted against 

















Legend to Fig. 5.5 
Mean exercise duration is expressed in seconds ±SEM. 
LVEF Category 1 =a LVEF >40 %, 2 =a LVEF of 36 -40 %, 3 =a LVEF 31- 
35%, and 4 =a LVEF <30 %. ANOVA was significant at p <0.0001. Only 








Legend to Fig. 5.6 
Mean exercise duration is expressed in seconds ±SEM. 
LVEF Category 1 =a LVEF >40 %, 2 =a LVEF of 36 -40 %, 3 =a LVEF 31- 
35%, and 4 =a LVEF <30 %. ANOVA was significant at p <0.0001. Only 




Exercise Time and Left Ventricular Systolic Dysfunction and 
Symptoms 
LVEF Group Exercise Time secs (SD) n p value 
Males 
LVSD 606 (119) 19 
No LVSD 740 (162) 594 0.0001* 
*SLVSD 523 (60) 6 
*ASLVSD 652 (122) 12 
S No LVSD 623 (160) 38 
A No LVSD 747(160) 543 <0.001LI' 
Females 
LVSD 356 (175) 9 
No LVSD 652 (150) 659 0.001* 
*SLVSD 299(157) 5 
*ASLVSD 387(211) 3 
S No LVSD 555(187) 67 
A No LVSD 665(140) 571 <0.001T 
Legend to Table 5.2 
LVSD represents left ventricular systolic dysfunction and refers to a 
LVEF<30% irrespective of symptoms. No LVSD is a LVEF >30 %, irrespective 
of symptoms. The letter S denotes "symptomatic" i.e the presence of cardiac 
dyspnoea or loop diuretic therapy, the letter A signifies asymptomatic subjects 
i.e those without cardiac d s noes and not taking loop diuretics. The *p value 
refers to a Student's t test between the two means. t4iP value denotes ANOVA 
for the groups shown. Further testing between the individual means SLVSD, 
ASLVSD and ASLVSD and No LVSD for both men and women was not 
statistically significant. *Two subjects had not completed the MRC 
Breathlessness Questionnaire and could not be assigned as 
symptomatic /asymptomatic. 
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Table 5.3 shows the mean exercise durations for men and women, divided by 
age group and the presence or absence of a LVEF <_30% and >30 %. Effort 
capacity diminishes with age and, with the exception of one group in men 
aged 35 -44 (where there is only one subject with left ventricular systolic 
dysfunction), the presence of left ventricular systolic dysfunction confers a 
lower mean exercise time. 
In a multivariate regression analysis performed on all subjects, the 
independent predictors of a lower exercise time were increasing age 
(p <0.0001), female sex (p <0.0001), current smoking (p <0.0001), increasing 
body mass index (p <0.0001), the presence of IHD (p <0.0001), left ventricular 
systolic dysfunction (p= 0.002) and hypertension (p= 0.038). 
5.3.5 Left Ventricular Systolic Dysfunction and Exercise Induced 
Ischaemia 
The prevalence of ST segment depression in subjects with left ventricular 
systolic dysfunction was 33% (7/21) compared to 24% (295/1243) in those 
without left ventricular systolic dysfunction (P =0.31 odds ratio [95% 
confidence intervals] 1.6 [0.6,4.0], Chi square). Men and women either 
symptomatic or asymptomatic were considered together to provide sufficient 
numbers for analysis. 
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Table 5.3 
Exercise Time and Left Ventricular Systolic Dysfunction 
MALES 
Age Group 





25 -34 870 (82) 117 
35 -44 809 (126) 123 828 1 
45 -54 739 (136) 113 674 (129) 7 
55 -64 678 (142) 126 536 (40) 5 
65 -74 603 (166) 115 547 (61.8) 6 
FEMALES 
Age Group 





25 -34 751 (90) 122 
35 -44 766 (104) 154 
45 -54 668 (127) 134 420 (196) 4 
55 -64 591 (149) 128 168 1 
65 -74 530 (163) 121 339 (158) 4 
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5.4 DISCUSSION 
The results presented in this chapter show, for the first time, that left 
ventricular systolic dysfunction, in subjects randomly sampled from the 
general population significantly impairs effort capacity. The average 
reduction for men was over 2 minutes, and for women nearly 5 minutes, less 
than subjects whose left ventricular ejection fraction was >than 30 %. 
The data for symptomatic left ventricular systolic dysfunction show a marked 
reduction compared to those without left ventricular systolic dysfunction in 
keeping with the syndrome of CHF severely limiting physical functioning 
(Stewart et al. 1989). Also of importance is the finding that asymptomatic 
individuals with left ventricular systolic dysfunction had a trend towards 
reduced effort capacity (a reduction of 88 secs in men and 265 secs in 
women). This was more impressive if compared with the effort capacities of 
asymptomatic subjects within the general population (a reduction of 95 secs 
for men and 275 secs for women ) when the findings did achieve statistical 
significance for men. The lack of statistical significance in women is almost 
certainly due to the small numbers with asymptomatic left ventricular systolic 
dysfunction. This observation lends weight to the earlier hypothesis, in this 
thesis, that the asymptomatic left ventricular systolic dysfunction identified in 
this study is biologically important. As both reduced ejection fraction and 
decreased exercise duration are powerful independent predictors of 
prognosis in symptomatic left ventricular systolic dysfunction, the finding of 
both these variables being depressed in asymptomatic left ventricular systolic 
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dysfunction in this population suggests that the likely natural history of the 
asymptomatic left ventricular systolic dysfunction will be progression to CHF. 
In CHF where evaluation of symptoms is too subjective to judge severity, 
exercise testing remains an important means of assessing functional capacity. 
In this study, we have confirmed using an objective method that the left 
ventricular systolic dysfunction identified is associated with a significant 
impairment of aerobic capacity. The STEEP Protocol, used in this work, 
generates a linear relationship between oxygen consumption and exercise 
duration, allowing the latter to be used as a surrogate for peak VOZ 
(Northridge et al. 1990, Riley et al. 1992). Translating the exercise durations 
in those with left ventricular systolic dysfunction to oxygen uptakes reveals 
the extent of impairment in aerobic capacity which was found. Thus for 
symptomatic left ventricular systolic dysfunction the mean peak VOZ was 
18mis /kg /min for men and 12mis /kg /min for women and for asymptomatic left 
ventricular systolic dysfunction, it was 22mis /kg /min in men and 15mis /kg /min 
in women. 
Comparisons with other work are limited due to the unique combination of 
exercise testing and echocardiography in this cross -sectional population 
sample. This study has reproduced the poor correlation between resting left 
ventricular ejection fraction and exercise capacity, when treated as a 
continuous variable ( Franciosa et al. 1981) but shown the expected 
relationship between a reduced left ventricular ejection fraction and effort 
capacity. 
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The decision to choose an ejection fraction cut -off of .30% is vindicated by 
the exercise results. Effort capacity was not significantly reduced until a value 
of <_30% was reached. 
The earlier finding of IHD being the predominant determinant of left 
ventricular systolic dysfunction in this population was also confirmed by the 
finding that half the subjects with left ventricular systolic dysfunction had 
evidence of exercise induced significant ST segment depression. 
This chapter, by demonstrating that effort capacity is reduced in those with 
ejection fractions _ <30 %, adds to the total picture of left ventricular systolic 
dysfunction in this population by highlighting that the physical debility caused 
by symptomatic left ventricular systolic dysfunction is also present, albeit to a 
lesser degree, in asymptomatic left ventricular systolic dysfunction. That the 
left ventricular systolic dysfunction identified was significantly associated with 
ischaemia confirms that the left ventricular systolic dysfunction in this 
community would be worthy of further investigation and management. 
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Chapter 6 
Biochemical Detection of Left Ventricular Systolic 
Dysfunction in an Urban Population 
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6.1 INTRODUCTION 
The syndrome of chronic heart failure (CHF) is a common, lethal and 
disabling condition, mainly attributable to left ventricular systolic dysfunction 
(McKee et al. 1971, The SOLVD Investigators, 1991). CHF, itself, often lies 
at the end stage of a progressive deterioration of LV function, which can 
remain asymptomatic for years. The work presented earlier in this thesis has 
shown that the asymptomatic form of left ventricular systolic dysfunction is as 
prevalent as CHF. We now, also, have compelling evidence demonstrating 
that treatment with ACE inhibitors reduces mortality and morbidity in patients 
with left ventricular systolic dysfunction, be it symptomatic or asymptomatic 
(Swedberg et al. 1987, The SOLVD Investigators, 1992). 
Detecting those with symptomatic and asymptomatic left ventricular systolic 
dysfunction is crucial in reducing the substantial mortality and morbidity 
associated with CHF. However, the clinical diagnosis of CHF is unreliable 
(Wheeldon et al. 1993a) and the asymptomatic precursor is clinically silent. 
While population screening by echocardiography might provide a solution, it 
would not be a cost effective one - a biochemical option would seem more 
attractive. 
The C and N terminals of atrial natriuretic peptide (C -ANP and N -ANP) are 
predominantly secreted by the atria in response to the stretch which occurs 
with the increased left atrial pressure associated with CHF (Glenbotski et al. 
1988). The circulating concentrations of both these peptides are raised in 
patients with symptomatic left ventricular systolic dysfunction (Francis et al. 
1990, Lerman et al. 1993). The levels of N -ANP are higher reflecting 
its 
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longer half life due to reduced renal clearance (Sundsfjord et al. 1988). More 
recently plasma concentrations of brain natriuretic peptide (BNP), 
predominantly produced by the ventricles, have also been shown to be 
elevated in patients with symptomatic left ventricular systolic dysfunction (Wei 
et al. 1993, Motwani et al. 1993). Moreover, N -ANP and BNP concentrations 
are also raised in patients with asymptomatic left ventricular systolic 
dysfunction (Lerman et al. 1993, Motwani et al. 1993). 
No previous work has addressed the question of population screening for left 
ventricular systolic dysfunction using the natriuretic peptides. This chapter 
reports on the first epidemiological study in which the utility of N -ANP and 
BNP to identify left ventricular systolic dysfunction has been evaluated. 
6.2 METHODS 
The methods involved are as described in the Chapter 2: it involves 1252 
subjects who had an analysable echocardiogram (LVEF, a questionnaire, 
ECG and a venous blood sample available for measurement of plasma N- 
terminal atrial natriuretic peptide (N -ANP) and brain natriuretic peptide (BNP). 
6.2.1 Definitions 
IHD is defined as a history of angina and /or current use of nitrates and /or a 
history or ECG evidence of MI and /or ECG criteria for major or minor 
ischaemia. Left ventricular systolic dysfunction pertains to a LVEF <_30 %. 
6.2.2 Statistics 
Natriuretic peptide concentrations are expressed as medians with 
interquartile ranges in parentheses. Differences in concentration between the 
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natriuretic peptides in those with and without significant left ventricular systolic 
dysfunction and between those with symptomatic and asymptomatic left 
ventricular systolic dysfunction compared to those with normal LV function 
were tested using the Kruskall -Wallis test. Differences between the individual 
categories of LVEF (1 -4) were assessed overall by the Kruskall -Wallis test, 
differences between the individual categories e.g. 1 and 2, 2 and 3, and 3 and 
4 were compared using the Mann -Whitney U test. A multiple logistic 
regression model was used to determine independent predictors of left 
ventricular systolic dysfunction. Variables included in the model were a 
history of MI, a history of angina, hypertension, an "abnormal ECG ", BNP and 
N -ANP concentrations. Receiver operator characteristic (ROC) curves were 
constructed to determine the sensitivity and specificity of BNP and N -ANP 
throughout the range of concentrations to detect left ventricular systolic 
dysfunction. The area under the ROC curve (AUC) was estimated according 
to the method of Hanley and McNeill (Hanley and McNeill, 1982) and provides 
a measure of the overall diagnostic accuracy of the test. The optimum BNP 
concentration for the calculation of positive and negative predictive 
accuracies was determined from the ROC analysis by addition. 
6.3 RESULTS 
Table 6.1 shows the characteristics of the study population. 1252 subjects 
had an analysable echocardiogram, a questionnaire, ECG and a venous 
blood sample available. 
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Table 6.1: Characteristics of the Population (Aged 25 -74) 
Age 
Sex 
mean 50.9 (SD14) 
male 49.1% (615) 
Evidence of IHD 24% (289) 
Evidence of MI 4.3% (80) 
History of angina 11% (134) 
ECG ischaemia 14.6% (179) 
ECG abnormal 21.9% (268 
Breathless 10 %(122) 
Hypertension 23.5% (291) 
Diabetes 2.6 %(32) 
Left ventricular systolic dysfunction (LVSD) 3.0 %(37) 
Asymptomatic LVSD 51% (19) 
Symptomatic LVSD 49% (18) 
Cardiac Dyspnoea 5 
Treated 8 
Treated and Dyspnoeic 4 
Legend to Table 6.1: IHD (Ischaemic Heart Disease) refers to either a history of angina or 
treatment with nitrates or a history of myocardial infarction (MI) or ECG evidence of q waves, 
left bundle branch block (LBBB) or a significant ST/T segment abnormality. Evidence of MI is 
defined as a history of MI or the presence of pathological Q waves on the ECG. ECG 
ischaemia is the presence of a pathological Q wave, LBBB or a significant ST/T segment 
abnormality. An abnormal ECG is defined as those abnormalities constituting ECG ischaemia 
and /or the presence of voltage criteria for left ventricular hypertrophy and /or atrial 
fibrillation /flutter. Breathlessness refers to cardiac dyspnoea according to the MRC 
Breathlessness Questions (in the absence of cough and /or sputum production for more than 
3 
days of the week for 3 months of the year). Hypertension is a measured blood pressure 
of 
>160mmHg systolic and /or 95mmHg diastolic and or current treatment with 
an 
antihypertensive. 
Diabetes is defined as a history of physician diagnosed diabetes 
and /or 
treatment with an oral hypoglycaemic agent and /or insulin. LVSD is a LVEF__30 %. Treated 




Thirty five subjects (3.0 %) had significant left ventricular systolic dysfunction 
of whom 51% (19) were symptomatic, 49% (18) were asymptomatic. 
Neither N -ANP or BNP were normally distributed. Log (e) transformation 
resulted in a normal distribution. Figures 6.1 and 6.2 show the scatter plots 
for log N -ANP and log BNP plotted against LVEF. It can be seen that any 
relationship that does exist between these variables is concentrated where 
the ejection fraction is lowest. 
The median concentration (interquartile range) of N -ANP in those with left 
ventricular systolic dysfunction was 2.8 (1.8,4.6) ng /ml compared to 1.3 
(0.9,1.8) ng /ml in those without left ventricular systolic dysfunction (p <0.001) 
(Figure 6.3). In subjects with symptomatic left ventricular systolic dysfunction, 
it was 3.3 (2.4,5.4) and in those with asymptomatic left ventricular systolic 
dysfunction, 2.2 (1.2,4.5) ng /ml. The BNP concentration, was similarly, 
significantly higher in subjects with left ventricular systolic dysfunction: 24.0 
(18,33) pg /ml compared to those with normal LV function: 7.7 (3.4,13) pg /ml, 
p <0.001.(Figure 6.4). The BNP concentration was highest in those with 
symptomatic left ventricular systolic dysfunction; 25(20, 33) and was lower in 
those with asymptomatic left ventricular systolic dysfunction; 23.4 (13.7,35.2), 
p <0.001. 
Figure 6.5 shows that the median concentration of N -ANP is only significantly 
raised once the LVEF is _ <30% (p- 0.0002) when compared with the category 
LVEF of 31 -35 %. The difference between those with an ejection fraction in 
the range 31 -35% and 36 -40% was not significant (p =0.5). The same 
analysis for BNP is depicted in Figure 6.6. However, the BNP median 
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Figure 6.1 N -ANP and Left Ventricular Ejection Fraction 
Legend to Figure 6.1 Log N -ANP conc. (ng /ml) plotted against LVEF 
( %) for all subjects aged 25 -74. 
Figure 6.2 BNP and Left Ventricular Ejection Fraction 
Legend to Fig 6.2 Log BNP conc.(pg /ml) plotted against LVEF ( %) for 
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Legend to Fig 6.3: N -ANP concentrations are expressed as medians with 
the interquartile ranges displayed by the box and the range of 
concentrations by the vertical lines. 










No LVD LVD 
Legend to Fig 6 4:BNP concentrations are expressed as medians with 
the interquartile ranges displayed by the box and the range of 
concentrations by the vertical lines. 
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Legend to Figure 6.5: N -ANP concentrations are expressed in 
ng /ml as medians ± interquartile ranges (box). The range is displayed by the 
vertical line. Left ventricular systolic dysfunction (LVSD) Category 1 is >40 %, 
2= 36- 40 %,3= 31 -35% and 4= <_30 %. 
Figure 6.6 BNP Concentration and Categories of LVEF 
Legend to Figure 6.6: BNP concentrations are expressed in 
pg /ml as medians ± interquartile ranges (box). The range is displayed by 
the 
vertical line. Left ventricular systolic dysfunction (LVSD) Category 1 is >40 
%, 
2= 36 -40 %, 3= 31 -35% and 4= <_30 %. 
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concentration for the LVEF category 31 -35% [13(9,17)] is significantly higher 
than that obtained with a LVEF of 36 -40% [9.2(3.7,14.3)] p= 0.0001. It is only 
marginally elevated in the category 36 -40% compared to those with a 
LVEF >40% [7.2(3.1,12.4)] p =0.04. 
Tables 6.2 and 6.3 show the results of the univariate and multivariate 
regression analyses, respectively. In the multivariate model the most 
significant predictor of a reduced LVEF was the presence of IHD. A 50% 
increase in BNP and N -ANP concentrations were also powerful independent 
predictors of left ventricular systolic dysfunction [BNP (p= 0.0001) or N -ANP 
(p= 0.0001)]. The presence of BNP in the model displaced N -ANP. The odds 
ratio for a BNP increase of 50% being associated with left ventricular systolic 
dysfunction was 1.9 [1.5,2.4]. 
Figures 6.7, 6.8, 6.9 and 6.10 show ROC curves for varying concentrations N- 
ANP and BNP in diagnosing left ventricular systolic dysfunction in the entire 
population aged 25 -74, those over 55 yrs, subjects aged 25 -74 with IHD and 
subjects >55yrs with IHD, respectively. 
The area under the curves for BNP and N -ANP in all subjects, those >_55 
years, those with IHD, and subjects >_55 years with IHD are shown in Table 
6.4. BNP is superior to N -ANP in detecting systolic dysfunction. 
Table 6.5 gives the sensitivity, specificity, positive and negative predictive 
accuracies for a BNP of >_17.9pg /ml in the detection of a LVEF530 %. For 
diagnosing left ventricular systolic dysfunction in all subjects aged 25 -74, the 
sensitivity was 76% (specificity 87 %). Confining the analysis to subjects aged 
25-74 with IHD gave a superior sensitivity of 84% (specificity 76 %) 
in 
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Table 6.2 : Univariate Logistic Regression Analysis 
Variable p value Odds Ratio [95% Confidence Intervals] 
Sex (male) 0.013 2.4 [1.2,4.8] 
Age 0.0001 1.07[1.04,1.10] 
Diabetes 0.0001 12.5[5.3,33.3] 
Breathlessness 0.005 3.0[1.4,6.6] 
ECG Abnormality 0.0001 8.3[4.2,16.7] 
IHD 0.0001 20.0[7.7,50.0] 
Hypertension 0.0001 5.6[2.9,11.1] 
BNP 0.0001 2.0[1.7,2.5] 
N -ANP 0.0001 1.8[1.5,2.2] 
Legend to Table 6.2: IHD is ischaemic heart disease. The definitions of the variables are 
contained in the legend to Table 1. The p values for BNP and N -ANP are for concentrations of 
the peptides which are increased by 50 %. 
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Table 6.3: Multivariate Logistic Regression Analysis 
Variable p value Odds Ratio [95 %CI] 
Sex(male) 0.008 3.1 [1.4,7.1] 
Diabetes 0.004 5.0 [1.7,14.3] 
IHD 0.0001 7.7. [2.9, 20.0] 
BNP 0.0001 1.9 [1.5,2.4] 
Legend to Table 6.3: 
IHD refers to ischaemic heart disease. The definitions are the same as in the legend to Table 
1. BNP refers to a 50% increase in the concentration of Brain Natriuretic Peptide. The odds 
ratios are quoted with the 95% confidence intervals [CI] in parentheses. 
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Figure 6.7: Receiver Operator Characteristic Curve for BNP 
and N -ANP in the Detection of Left Ventricular Systolic 
Dysfunction in all Subjects Aged 25 -74. 
Legend to Figure 6.7: Receiver Operator Characteristic (ROC) 
Curves for varying concentrations of BNP (solid lines) and 
N -ANP (broken lines) to detect left ventricular systolic dysfunction in 
subjects aged 25 -74 
Figure 6.8: Receiver Operator Characteristic Curve for BNP 
and N -ANP in the Detection of Left Ventricular Systolic 
Dysfunction in all Subjects Over 55 Yrs. 
Legend to Figure 6.8: Receiver Operator Characteristic (ROC) Curves 
for 
varying concentrations of BNP (solid lines) and N -ANP (broken lines) 
to 
detect left ventricular systolic dysfunction in subjects aged over 55 yrs. 
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Figure 6.9: Receiver Operator Characteristic Curve for BNP 
and N -ANP in the Detection of Left Ventricular Systolic 
Dysfunction in Subjects Aged 25 -74 With IHD. 
Legend to Figure 6.9: Receiver Operator Characteristic (ROC) 
Curves for varying concentrations of BNP (solid lines) and 
N -ANP (broken lines) to detect left ventricular systolic dysfunction in subjects 
aged 25 -74 with IHD. 
Figure 6.10: Receiver Operator Characteristic Curve for 
BNP and N -ANP in the Detection of Left Ventricular 
Systolic Dysfunction in Subjects Over 55 Yrs With IHD. 
Legend to Figure 6.10: Receiver Operator Characteristic (ROC) 
Curves for varying concentrations of BNP (solid lines) and 
N -ANP (broken lines) to detect left ventricular systolic dysfunction in 
subjects 
over 55 yrs with IHD. 
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Table 6.4: Areas Under Receiver Operator Characteristic 
Curves 
Population BNP N -ANP 
All subjects aged 25 -74 0.882 (0.03) 0.753(0.05) 
Subjects aged 25 -74 with IHD 0.841 (0.03) 0.709(0.06) 
Subjects >_55 years 0.858 (0.03) 0.723(0.05) 
Subjects >_55 years with IHD 0.843 (0.03) 0.704 (0.06) 
Legend to Table 6.4: The areas under the curves are quoted with the standard deviation in 











































































































































































































































































































































detecting left ventricular systolic dysfunction. Restriction of the analysis to 
subjects >_55 years is associated with an improvement in the sensitivity to 
89% (specificity 71%). Targeting the analysis further to subjects >_55 years 
who have IHD results in the optimum sensitivity of 92% with a reduction in 
specificity to 72 %. Defining left ventricular systolic dysfunction as a 
LVEF <_35 %, BNP still performs better than N -ANP. A BNP concentration of 
>_17.9pg /ml results in a 43% sensitivity (specificity 88 %) in the detection of a 
LVEF <_35 %. This pattern of a lower sensitivity with a specificity, similar to that 
obtained with a LVEF30 %, is found in all age groups, irrespective of the IHD 
status. 
Combining the two peptides i.e using a BNP concentration of >_17.9pg /ml 
and/or a N -ANP concentration of >_1.76ng /mI does result in an improved 
sensitivity for the detection of left ventricular systolic dysfunction in the entire 
population, the combination is 84% sensitive (66% specific). However, in all 
age groups, and irrespective of the IHD status, the specificity is less. Analysis 
based on logistic regression did not reveal any added predictive value of N- 
ANP after BNP was included in the model. 
6.4 DISCUSSION 
This work presented in this chapter confirms that BNP and N -ANP 
concentrations are elevated in subjects with LV systolic dysfunction. 
Importantly, they are also raised in subjects with asymptomatic left ventricular 
systolic dysfunction. While this fact has been demonstrated 
in patient 
Populations, particularly, post myocardial infarction, this work is 
the first to 
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report that asymptomatic subjects with left ventricular systolic dysfunction, 
sampled from the general population have high circulating levels of natriuretic 
peptides. 
The results presented in this chapter also have bearing on the left ventricular 
ejection fraction cut -off below which left ventricular systolic dysfunction can be 
said to be present in this population. N -ANP does not become significantly 
elevated until the ejection fraction is .30%, which lends weight to the earlier 
decision to choose values below this cut -off to indicate definite left ventricular 
systolic dysfunction. However, it is apparent that BNP is significantly elevated 
in subjects whose left ventricular ejection fraction is in the range of 31 -34% 
(although the median value is much less). Indeed the average BNP 
concentration in subjects whose ejection fraction is between 35 and 40% is 
still marginally, though significantly higher, than those above 40 %. This 
should serve to reiterate the earlier point that the cut point chosen for definite 
left ventricular systolic dysfunction is both arbitrary and strict. Undoubtedly, 
there are some subjects in the range of 31 -40% who have biologically 
abnormal ventricular function. The fact that BNP is raised and not N -ANP 
presumably reflects its ventricular origin. It appears, in this work, to be a 
more sensitive indicator of ventricular dysfunction. This work also calls into 
question the currently accepted gold standards for left ventricular systolic 
function. It is clear that there is no absolute cut -off below which 
left 
ventricular systolic dysfunction can be definitely said to be present. It 
may 
depend on the premorbid value such that 43% for a person who was 
at 65% 
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could be significant. BNP, itself, may prove to be a superior marker of LV 
function than echocardiographic ejection fraction. 
A raised BNP concentration appears to have greater accuracy than N -ANP in 
detecting left ventricular systolic dysfunction. This is in agreement with the 
work of others where BNP is emerging as a superior diagnostic marker of left 
ventricular systolic dysfunction (Wei et al. 1993, Yamamoto et al. 1996, 
Omland et al. 1996b) although in one post MI study N -ANP was more closely 
associated with a reduced left ventricular ejection fraction (Omland et al. 
1996a). 
This study also shows that BNP has acceptable accuracy to be used as a 
diagnostic tool for detecting left ventricular systolic dysfunction in the whole 
population. However, widespread population screening for left ventricular 
systolic dysfunction is unlikely to be cost effective. Targeting the use of this 
test to individuals at high risk of developing left ventricular systolic dysfunction 
would lead to a more economical use of further investigation such as 
echocardiography or radionuclide ventriculography. This work and others 
have shown that the prevalence of CHF and left ventricular systolic 
dysfunction rises with age (McKee et al. 1971). The present data confirms 
that tailoring the analysis to subjects of 55 years and over improves the 
sensitivity of the test. As 83% of subjects with left ventricular systolic 
dysfunction had some evidence of IHD (93% of those >_ 55 years ), further 
restriction of the screening to older subjects with IHD results in the optimum 
sensitivity of the test at 92% with a reduction in the specificity to 
72 %. It 
should also be noted from the logistic regression model that BNP does 
add 
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incremental value to IHD in the detection of left ventricular systolic 
dysfunction. 
As this is the first study to investigate the use of peptides as screening tools 
in the general population, comparison with other studies which have 
addressed this in patient populations poses some problems. Omland et al 
(Omland et al. 1996b) found the overall accuracy of BNP in detecting mild left 
ventricular systolic dysfunction (defined as an angiographic LVEF45 %) in 
subjects undergoing routine cardiac catheterisation to be only modest (AUC 
0.789) in comparison to these results. This may be explained by this study 
seeking to find significant systolic dysfunction- an ejection fraction <_30 %. This 
was chosen as a cut off value as it represented a significant (33 %) reduction 
on the mean value for LVEF in this population where it is reasonably certain 
that true biological and not merely statistical abnormality has been detected 
(LVEF was normally distributed). Differences in the methods used to 
determine left ventricular function between studies e.g. echocardiography, 
radionuclide ventriculography or angiography (which have known 
discrepancies in the normal range of ejection fraction) diminish the value of 
comparisons of absolute sensitivity and specificity. Bearing this in mind, 
these results are similar to those of Yamamoto et al (Yamamoto et al. 1996) 
who quoted BNP as having a 81% sensitivity (specificity 81%) and N -ANP 
as 
67% sensitive (63% specific) in diagnosing a LVEF45% in 94 subjects 
undergoing cardiac catheterisation for suspected cardiac disease. This work 
is also comparable to that of Davis et al (Davis et al. 1994) who report 
a BNP 
concentration 
of >22pg /ml as having an 80% sensitivity (70% specificity) 
for 
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diagnosing left ventricular systolic dysfunction, defined as a LVEF550% in an 
acutely breathless group of patients. However, in that study BNP had an 
impressive 93% sensitivity (specificity 90 %) for diagnosing heart failure as the 
cause of dyspnoea. 
The results obtained in this study using BNP to detect left ventricular systolic 
dysfunction in the general population are also similar to work which has 
examined its use in the post infarct population (Choy et al. 1994) 
The results for N -ANP are much less encouraging than those of Lerman et al 
(Lerman et al. 1993) where N -ANP had both a sensitivity and specificity of 
>90% for detecting asymptomatic left ventricular systolic dysfunction. This 
may be due to the low values of N -ANP in the control group in that study. In 
the present study there is a considerable scatter of both BNP and N -ANP 
concentrations in those without left ventricular systolic dysfunction. This may 
reflect the fact that, owing to the study design, sampling had to be carried out 
at varying times throughout the day. In addition, in this work the values 
obtained for the natriuretic peptides are not age corrected and the study did 
not employ any of the usual exclusion criteria applied to those taking part in 
clinical trials e.g. renal failure. These data, as such, provide an insight into the 
use of these peptides in routine clinical practice. The sensitivity results for 
BNP in the general population represent the "worst case scenario" as they 
will 
include some individuals with left ventricular systolic dysfunction on treatment 
for CHF and who may well have low BNP values. Similarly, an elevated 
BNP concentration in the absence of left ventricular systolic dysfunction 
could 
represent a false positive result. Alternatively, the result 
could be 
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misclassified due to the strict definition of systolic dysfunction used or could 
be elevated as a result of left ventricular hypertrophy or renal dysfunction. 
The very high negative predictive value of BNP in the detection of left 
ventricular systolic dysfunction gives the best insight into how this test might 
be used clinically: a BNP concentration of <17.9pg /ml in this study meant the 
presence of left ventricular systolic dysfunction was highly unlikely. 
The meticulous handling of the samples, employed in this work (from supine 
patients, immediate spinning in a refrigerated centrifuge and plasma storage 
at -20 °C) would not be acceptable in the primary care setting. However, it is 
now well known that N -ANP and BNP have impressive in vitro stability 
(Omland et al. 1996a, Davidson et al. 1995, Murdoch et al. 1997b) allowing 
meaningful measurements to be performed in blood which has been stored 
for up to 72 hours. Results in this work were also obtained using 
radioimmunoassays for N -ANP and BNP which required prior extraction - a 
time consuming process which would restrict the use of this measurement to 
specialist tertiary referral centres. Rapid direct assays for these peptides are 
now available and would widen their possible use making them suitable for 
use in primary care. 
The accuracy of BNP for the detection of left ventricular systolic dysfunction is 
comparable with that of prostate specific antigen (AUC of 0.94) (Jacobsen 
et 
al. 1996) and is superior to mammography for breast carcinoma (0.85) (Swets 
et al. 1991) and Papanicolaou smears (0.70) (Fahey et al. 1995). 
The 
accuracy of prostate specific antigen can be improved by using age 
specific 
cut -offs to improve the sensitivity in younger men and the specificity 
in older 
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subjects to improve the cost effectiveness of the test. Similar refining of the 
BNP assay might improve its cost effectiveness. 
CHF is a common, serious condition, with a recognisable latent phase which 
has a treatment known to both reduce mortality and progression. This 
chapter has shown that detecting symptomatic individuals or screening high 
risk subjects for left ventricular systolic dysfunction using elevated plasma 
concentrations of natriuretic peptides merely awaits the further development 
of a "near patient" assay accessible to primary care physicians. 
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Chapter 7 
The Effect of the Angiotensin Converting Enzyme 
Insertion /Deletion Polymorphism on Left Ventricular Systolic 
Dysfunction in an Urban Population 
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7.1 INTRODUCTION 
The renin angiotensin system plays an important role in regulating ventricular 
structure and function (Harrap et al. 1996, Foult et al. 1988). Angiotensin II 
has trophic effects on cultured cardiomyocytes (Baker and Aceto, 1990). 
Experimentally, it causes ventricular hypertrophy by an action which may be 
largely independent of its pressor effects (Geenen et al. 1990) Similarly, in 
healthy young adults plasma angiotensin II concentration correlates with left 
ventricular mass, independently of systolic blood pressure (Harrap et al. 
1996). Conversely, a non -hypotensive dose of an ACE inhibitor can regress 
left ventricular hypertrophy (Slinz et al. 1992). Angiotensin Il also has a 
positive inotropic effect and, in humans, intracoronary administration of an 
ACE inhibitor reduces cardiac contractility (Foult et al. 1988, Schomish et al. 
1990). 
Recently, an insertion deletion (I /D) polymorphism related to the 
presence /absence of a 287 bp fragment in the 16th intron of the angiotensin 
converting enzyme (ACE) gene has been identified (ACE /I /D polymorphism) 
(Rigat et al. 1990). The deletion (D) is codominantly associated with 
circulating ACE concentration and activity, whereby homozygotes for the D 
allele have a mean serum ACE activity which is almost fifty percent higher 
than that of subjects with the II genotype (Rigat et al. 1990). ACE activity 
in 
tissues, including myocardium, is also increased in D allele homozygotes 
(Costerousse et al. 1993, Danser et al. 1995). 
The rate of conversion of angiotensin I to angiotensin II is increased 
in the 
small arteries from subjects with the D allele, as is the physiological 
response 
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to angiotensin I (Buikema et al. 1996). These observations suggest that the 
ACE I/D polymorphism might also influence ventricular structure and function. 
This part of the study investigates the relationship between the ACE I/D 
polymorphism, left ventricular mass and left ventricular ejection fraction in a 
large cross -sectional population study. 
7.2. METHODS 
7.2.1 Subjects and Population 
The study population is described in Chapter 2. The definition of IHD, 
hypertension and ECG abnormalities are identical to those used earlier. 
7.2.2 Statistical Analysis 
The analyses were based on the calculation of odds ratios to provide an 
estimate of relative risk for the various manifestations of "coronary heart 
disease" i.e MI, ECG major or minor ischaemia. The effect of the ACE D 
allele was assumed to be co- dominant with codes 0,1 or 2 being applied 
according to the number of D alleles. The association between the ACE 
genotypes and left ventricular ejection fraction was determined by linear 
regression analysis. A p value of <0.05 is taken as statistical significance. 
7.3 RESULTS 
7.3,1 Baseline Characteristics of Subjects 
The baseline characteristics of the screened subjects are as summarised 
in 








a measured Ejection 
Fraction 
(n =1467) 
Age mean (SD) 50.8(14) 50.4(14.1) 
range 25 -74 25 -74 




Self reported MI 5.2% 5.1% 
Diabetes 3.1% 2.7% 
Hypertension 31.8% 30.7% 
SBP(mmHg) mean(SD) 133(23) 133(23) 
DBP(mmHg) mean(SD) 78(12) 78(12) 
Body Mass Index 
(kg /m2) mean(SD) 26.2(4.9) 26.0(4.3) 
Cholesterol (total) mg /ml mean(SD) 6.07(1.23) 6.07(1.24) 
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7.3.2 Distribution of ACE genotypes 
The distribution of the DD, ID and II genotypes in the screened population 
was 28.4 per cent, 48.2 per cent and 23.4 per cent respectively. There was 
an overall frequency of 52.5 per cent for the D allele and 47.5 per cent for the 
I allele. This genotype distribution was not significantly different from that 
assuming Hardy -Weinberg equilibrium and compares closely with that of 
other white populations studied (Schunkert et al. 1994, Gardemann et al. 
1995, Cambien et al. 1992, Mattu et al. 1995). 
7.3.3 ACE Genotype and ECG evidence of IHD 
Subjects were categorised according to the presence or absence of minor 
and major ECG abnormalities and ECG evidence of myocardial infarction as 
described in Chapter 2. This was possible in 1482 individuals. The ACE 
genotype frequencies in each of these patient categories is shown in Table 
7.2. The D allele of the ACE deletion polymorphism was significantly more 
frequent in patients with a major ECG abnormality or ECG evidence of 
myocardial infarction, with an odds ratio for DD versus II of 1.53 (p= 0.031). 
7.3.4 ACE Genotype and LVEF in Patients With IHD 
As anticipated, an association was found between ECG evidence of 
ischaemia /infarction and left ventricular ejection fraction (LVEF). Patients with 
ECG evidence of ischaemia /infarction, the majority of whom were over the 
median age of the population of 51 years, had a lower LVEF (Table7.3). (The 
association between LVEF and these ECG abnormalities was only significant 
for subjects > than the median age of 51 years ). 
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Normal 27% (337) 49% (599) 24% (293) 
Minor 35% (7) 40% (8) 25% (5) 
Major 33% (65) 49% (97) 19% (37) 
MI 41% (14) 35% (12) 24% (8) 
Major or MI 34% (79) 47% (109) 19% (45) 
Legend to Table7.2 The D allele was significantly more frequent in subjects 
with a major ECG abnormality or ECG evidence of MI. (Odds Ratio: DD 
versus Il of 1.53 and for ID versus II of 1.18, p =0.031 for trend.) 
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Table 7.3: LVEF in Patients With IHD 
<51 years >51 years 
ECG Category Mean LVEF ±SD(n) Mean LVEF ±SD(n) 
Normal 47.2% ±6.8(601) 46.5% ±7.7(502) 
Minor 47.3% ±4.0(3) 48.7 % ±5.6 (14) 
Major 49.0% ±8.5(35) 43.2% ±12.2 (137) 
MI 49.7% ±4.4(8) 41.3% ±11.7(23) 
Legend to Table 7.3 The association between and ECG major /MI categories 
and LVEF% was significant at p <0.0001 in subjects age >51 years. 
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An association was also found between the ACE gene polymorphism and 
LVEF in patients with ECG evidence of IHD (Table 7.4). The average LVEF 
in patients with the D allele was significantly higher than in II homozygotes 
(p <0.02). Significantly fewer patients with the D allele had severely 
depressed left ventricular function (i.e. LVEF <35% or LVEF <30 %) (Table 
7.4). 
7.3.5 ACE Genotype, LVEF and Left Ventricular Dimensions 
In support of the above findings, DD homozygotes with reduced ejection 
fractions had smaller left ventricular dimensions. For example, mean left 
ventricular diastolic dimension in ischaemia /infarction subjects with the DD 
genotype was 4.93 cm whereas it was 5.64 cm in II homozygotes (Table 7.5). 
7.3.6 ACE Genotype, Systolic Blood Pressure and LVEF 
The relationship between systolic blood pressure, the ACE I/D polymorphism 
and LVEF is shown in Table 7.6. LVEF was higher in older subjects (age > 
median) with a higher systolic blood pressure (> median) who had the D 
allele. Subjects of this type who had the DD genotype had a mean LVEF of 
47.5 per cent compared to those with the II genotype who had a mean LVEF 
of 44.6 per cent (p= 0.012). This relationship was found both in subjects with 
a normal ECG (P <0.04) and in those with ECG evidence of 
ischaemia /infarction (p <0.03) (Table 7.7). Subjects homozygous for the I 
allele, with a higher systolic blood pressure and an abnormal ECG, had the 
lowest LVEF (mean 41.0 per cent compared to 47.6 per cent in those who 
were DD genotype and had a lower blood pressure and normal ECG). 
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Table 7.4 : 
LVEF According to ACE Genotype in Subjects With ECG 
Evidence of Major Ischaemia I Infarction 
ACE genotype 
DD ID II 
LVEF (mean ±SD) 44.6 (12.2) 42.9 (11.5) 40 (13.1) 
Subjects with LVEF <30% 4 (7 %) 7 (9 %) 7 (24 %) 
Subjects with LVEF <35% 9 (16 %) 15 (20 %) 7 (24 %) 
Legend to Table 7.4 Effect of ACE I/D genotype on LVEF, p <0.02, effect of 
ECG ischaemia or infarction on LVEF, p <0.0002. The interaction between 
the ACE genotype and ECG /ischaemia and infarction was NS. Subjects were 
all >51 years, n =556. 
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Table 7.5 
ACE Genotype, Left Ventricular Ejection Fraction and 
Left Ventricular Dimensions in Subjects With Reduced 
Left Ventricular Ejection Fraction (LVEF <0.30) 
Genotype 
LVEF30% DD ID II 
Absent LVESD (cm) 3.35 3.34 3.37 
Absent LVEDD (cm) 4.94 4.94 5.01 
Present LVESD (cm) 3.58 3.64 4.30 
Present LVEDD (cm) 4.93 5.50 5.64 
Legend to Table 7.5. 
ACE I /D: effect on (LVESD) p <0.007 
effect on ( LVEDD) p <0.01 
The analysis refers to the 958 individuals with a LVEF< M -Mode 
echocardiogram and ACE I/D type. 
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Table 7.6 
ACE Genotype, Systolic Blood Pressure and LVEF In 
all Subjects >51 Years 
Mean LVEF ±SD(n) 
SBP >141 mmHg* SBP <141 mmHg 
DD (n) 47.5 %± 8.3(56) 44 %± 9.3(138) 
ID (n) 45.8 %± 9.6(107) 46 %± 8.6(234) 
II (n) 44.6 %± 8.8(53) 46.6 %± 9.9(106) 
Legend to Table 7.6 
SBP (systolic blood pressure) 
* Median SBP for those >51 years =141 mm Hg 
LVEF was significantly higher in subjects with a SBP >median value who had 
the D allele (p= 0.012). 
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Table 7.7 
ACE Genotype and LVEF 
in Subjects Over 51 Years With a Systolic Blood Pressure 
Greater Than the Median Value 
Normal ECG ECG major 
ischaemia or MI 
ACE genotype LVEF Mean ±SD (n) LVEF Mean ±SD (n) 
DD 47.6%±6.7(96) 47.1%±11.3 (42) 
ID 46.4%± 8.7(181) 43.5%±11.8 (52) 
I I 45.4%± 7.6(85) 41.0%±12.3 (21) 
Legend to Table 7.7 
The association between the D allele and LVEF was significant at p <0.04 for 
subjects with a normal ECG and at p <0.03 for those with ECG evidence of 
major ischaemia or MI. 
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7.3.7 ACE Genotype and Left Ventricular Hypertrophy 
No association was found between the ACE I/D polymorphism and left 
ventricular hypertrophy (LVH) (Table 7.8) in the 40 subjects with ECG criteria 
for LVH. Similarly there was no relationship between the ACE I/D status and 
echocardiographically measured left ventricular mass (Table 7.9) in the 1118 
subjects with this measurement available. The known effect of gender on left 
ventricular mass was, however, identified (Table 7.9). 
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Table 7.8 
ACE Genotype and Electrocardiographic 
Left Ventricular Hypertrophy 
%LVH (n) 
Men Women All 
DD 3.1(2) 1.0 (2) 2.1(4) 
ID 5.5(19) 1.9(7) 3.6(26) 
II 4.3(7) 1.6(3) 2.9(10) 
Legend to Table 7.8 
LVH denotes left ventricular hypertrophy. 




ACE Genotype and Echocardiographic Left Ventricular 
Mass 
LV Mass (g, mean ±SEM) 
Men Women 
DD 154.7 (3.6) 130.4 (3.3) 
ID 150.1 (2.6) 134.3 (2.4) 
II 154.6 (3.6) 129.2 (3.1) 
Legend to Table 7.9 
The effect of gender on LV mass was significant at p <0.0001. The 
analysis refers to the 1118 individuals with this measurement available. 
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7.4 DISCUSSION 
The study has a number of significant findings. It confirms, in a large cross 
sectional population survey, the association between the ACE I/D 
polymorphism and ischaemic heart disease, whereby the prevalence of ECG 
evidence of ischaemia or infarction is greater in subjects with the D allele 
(Gardemann et al. 1995, Cambien et al. 1992, Mattu et al. 1995, Samani et al. 
1996, Nakauchi et al. 1996). A novel and important additional finding is the 
association between the ACE I/D polymorphism and left ventricular ejection 
fraction (LVEF). LVEF was higher in older subjects with the D allele who had 
ECG evidence of ischaemia or infarction compared to similar patients who 
possessed the Il genotype. Similarly, it was found that possession of the D 
allele was associated with a higher LVEF in older subjects, with a systolic 
blood pressure above the population median. Each of these main findings is 
worthy of discussion. 
In their original case control study, Cambien et al reported an increased 
frequency of the ACE gene D allele in patients with myocardial infarction 
(odds ratio DD versus II 1.34) (Cambien et al. 1992). Of a large number of 
subsequent studies, the majority, but not all, (Lindpainter et al. 1996) have 
confirmed this association between the ACE I/D and polymorphism and the 
prevalence /incidence of myocardial infarction (and, also the prevalence and 
extent of coronary artery disease) (Gardemann et al. 1995, Cambien et al. 
1992, Mattu et al. 1995, Samani et al. 1996, Nakauchi et al. 1996). This 
study 
adds further evidence in favour of this association. 
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A more novel finding is the relationship of the ACE I/D polymorphism to left 
ventricular function, in patients with myocardial ischaemia /infarction. Left 
ventricular systolic dysfunction, characterised by a reduction in LVEF, is a 
common complication of myocardial infarction (MI). Left ventricular systolic 
dysfunction may be immediately apparent after MI or may develop over time 
through a process referred to as remodelling. The results show that LVEF 
was higher in subjects with myocardial ischaemia /infarction and the D allele. 
Specifically, mean LVEF in older subjects with ECG evidence of infarction 
was 44.6% in DD homozygotes compared to 40.0% in those with the Il 
genotype. An ejection fraction difference of 4.6 percentage points is of 
potentially great prognostic significance (The Multicentre Post Infarction 
Research Group, 1983, Cintron et al. 1993). The proportion of subjects with a 
significantly reduced ejection fraction (LVEF <30 %) in each of these two 
groups was 7% versus 24% respectively. These findings are supported by 
the observation that DD homozygotes have significantly smaller left 
ventricular end systolic and end diastolic dimensions. 
These results are possibly surprising in that subjects with the D allele might 
be expected to have been at greater risk of multiple infarction and, therefore, 
to have a lower LVEF. Similarly, it has been widely suggested that activation 
of the blood renin angiotensin system contributes to the decline of the LVEF 
in patients with LV dysfunction in a number of ways, including through 
alteration of ventricular loading conditions (Rouleau et al. 1993). Indeed, two 
short term serial follow -up studies after infarction have shown that survivors 
with the DD genotype were more likely to show ventricular dilation and 
a fall in 
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LVEF (Ohmichi et al. 1995, Pinto et al. 1995). Why this cross -sectional 
population survey reveals different findings from those serial studies in cases 
is not clear. One possibility is that there has been selective loss, through 
premature mortality, of low ejection fraction patients with the DD genotype. 
This would be in keeping with the existing observations outlined above, 
suggesting a detrimental cardiovascular effect of this genotype. 
On the other hand, the higher mean ejection fraction in the DD genotype 
groups may reflect a beneficial effect of the D allele on myocardial structure 
and function. Preservation of left ventricular systolic function and volume 
after myocardial infarction may depend on an adequate myocardial 
hypertrophic response. One of the characteristic changes following infarction 
is hypertrophy of the non -infarcted myocardium (Gaudron and et al, 1992). 
This is believed to limit or halt progressive remodelling by reducing or 
normalising left ventricular wall stress (wall stress is believed to be the major 
stimulus for the remodelling process). The blood renin angiotensin system 
and the ACE genotype D allele both appear to facilitate hypertrophy of the 
human left ventricle (Harrap et al. 1996, Schunkert et al. 1994, Danser et al. 
1995, Montgomery, 1996). For example, DD homozygotes show an 
increased myocardial hypertrophic response in hypertension (in some 
studies) (Schunkert et al. 1994, Rouleau et al. 1993, Abraham et al. 1995) 
and in response to exercise training (Montgomery et al. 1997). There is 
evidence from the pulmonary circulation to support this theory: patients with 
pulmonary hypertension who have the DD genotype have maintained cardiac 
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outputs and less right heart failure than those who are non -DD (Abraham et 
al. 1995). 
Despite the attractiveness of this theory, no significant association between 
the ACE I/D polymorphism and left ventricular mass in the subjects studied 
could be found. This lack of association could be real or could reflect a 
number of confounding factors. Firstly and most importantly, it was not 
possible to make an accurate assessment of LV mass in a large proportion of 
subjects. Disease and treatment factors also confound any analysis. 
Distortion of the normal LV spherical geometry by infarction invalidates the 
assumptions on which the calculation of LV mass is made. LV mass also 
increases after infarction. Anti -hypertensive therapy can reduce LV mass. 
These factors may have obscured a real association between LV mass and 
the ACE I/D polymorphism. 
Alternatively, therefore, it could simply be that DD homozygotes generate 
more myocardial angiotensin Il with its positive inotropic action (Foult et al. 
1988, Schomish et al. 1990). Either of these explanations would also fit with 
the relationship between LVEF and systolic blood pressure we also found and 
which is described below. There is, however, a third possible explanation for 
the findings in post- infarct survivors. After infarction, ACE activity increases 
in the infarcted segment of the myocardium and is believed to contribute to 
the development of a fibrous scar (Weber et al. 1995). Ability to rapidly lay 
down a rigid scar may lessen infarct segment expansion and ventricular 
dilation. Patients with the DD genotype may be better able to do this. 
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Other studies in patients with heart failure do not help in determining whether 
the DD genotype is detrimental or protective with respect to myocardial 
function. Raynolds et al, reported a greater prevalence of the ACE DD 
genotype amongst patients with end stage heart failure than in a normal 
control group (Raynolds et al. 1993). Whilst this has been interpreted as 
indicating that the DD genotype predisposes to myocardial failure, it is also 
possible that the DD genotype confers a survival advantage in these 
circumstances, i.e. these patients with advanced heart failure, undergoing 
transplantation, are selected survivors from the general population of patients 
with heart failure. Furthermore, other studies do not support an association 
between the ACE I/D polymorphism and heart failure (Sanderson et al. 1996, 
Andersson and Sylven, 1996, Montgomery et al. 1995). However, one recent 
study suggests that patients with heart failure, who have the DD genotype, 
have a worse prognosis (Andersson and Sylven, 1996). 
This study also found that subjects who were homozygotes for the D allele 
had a higher LVEF in the face of higher systolic blood pressures. As is the 
case following myocardial infarction, the heart's ability to preserve systolic 
function as blood pressure increases depends on its ability to hypertrophy. 
In older subjects with a normal ECG and a high systolic arterial pressure, 
mean LVEF was 47.6% in DD homozygotes versus 45.4% in those with the II 
genotype. In similar subjects with an ECG indicative of myocardial 
ischaemia /infarction, mean LVEF was 47.1% and 41.0 %, respectively. 
These findings lend support to the observations in patients 
with ECG 
evidence of infarction and one interpretation, discussed above. 
They are 
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also consistent with the recently reported observations of Montgomery et al. 
(Montgomery et al. 1997). These authors have shown that the DD genotype 
results in greater exercise training induced left ventricular hypertrophy in 
healthy young male adults. In other words, it seems that the ACE I/D 
polymorphism may modulate the common hypertrophic response to three 
separate stimuli to hypertrophy, i.e. infarction, hypertension and exercise 
training. 
In summary these findings raise the intriguing possibility that the ACE I/D 
polymorphism has a bi- directional effect in coronary heart disease. The DD 
genotype may predispose to infarction but may also protect the left ventricle 
from the insult of infarction or hypertension, at least in the short to medium 
term. The true effect of the ACE I/D polymorphism on myocardial structure 





The data presented in this thesis provides some novel information on the 
epidemiology of left ventricular systolic dysfunction in a typical, urban 
population in an industrialised society and raises some important issues of 
how best to detect it. Before summing up the major findings and their 
implications both for future research and clinical practice, it is necessary to 
discuss the definition of left ventricular systolic dysfunction used throughout. 
Crucial to any discussion on the prevalence of a condition is the premise on 
which its presence or absence is decided, in this case how to define abnormal 
left ventricular function according to the left ventricular ejection fraction. 
The method employed to detect left ventricular systolic dysfunction in this 
population -based study had to be non invasive. The left ventricular ejection 
fraction was chosen as it is a parameter of left ventricular systolic 
performance with both clinical and prognostic significance (Murray et al. 1974, 
Nelson et al. 1975) . It was also the index of left ventricular function used to 
recruit patients in the majority of the heart failure treatment and post MI 
ventricular dysfunction trials (which have vindicated the use of the angiotensin 
converting enzyme inhibitors as effective in reducing morbidity and mortality 
in CHF and asymptomatic left ventricular systolic dysfunction). It would not 
have been desirable to expose the general public to radiation, which ruled out 
the use of radionuclide ventriculography which does provide a more 
reproducible measure of left ventricular ejection fraction (Ray et al. 1995). In 
addition, echocardiography is a powerful investigative tool, is more widely 
available in hospitals in the UK than radionuclide ventriculography (Ray 
et al. 
1995), and provides more information than radionuclide methods 
regarding 
160 
the possible aetiology of left ventricular systolic dysfunction by its ability to 
interrogate valve function and wall motion. In this study the most accurate 
biplane method of assessing LVEF, that which correlates best with both 
angiographic and radionuclide measurements (Stamm et al. 1992) and the 
one which is most valid to use in the presence of a wall motion abnormality 
(Albin and Rahko, 1990) was used. The measurement was made 
meticulously, using the same scanning equipment and the same sonographer 
in two thirds of the studies. The conversion of the images to figures was done 
by a single analyser, making measurements in triplicate. The interobserver 
and intraobserver variation were similar to, or superior than, other 
echocardiographic studies. 
Unfortunately, there are no published echocardiographic population studies 
using this particular method available to us for comparison. Normal ranges 
cited in textbooks etc. are based on small samples of healthy volunteers. 
Defining abnormality could be likened, to some extent, as trying to define high 
or low blood pressure. Essentially there are two approaches. The first is to 
define "statistical" abnormality, taking any LVEF more than two standard 
deviations from the mean as abnormal and the second is to try and predict 
"biological" abnormality. The statistical approach would give a cut -off point of 
approximately 35 %. It would also, however, almost certainly include some 
biologically normal people, not least because of the problem of regression to 
the mean. The strength of this study lies in the collection of other important 
information allowing the determination, with reasonable certainty, 
as to 
whether or not the "abnormal" LVEF subjects were really 
biologically 
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abnormal. From the clinical history and ECG it is known whether or not the 
subjects had a reason to have systolic dysfunction. In addition there is 
physiological data to show whether or not there has been a compensatory 
response to a reduction in left ventricular function i.e. a rise in blood 
natriuretic peptide concentrations. Similarly, there is physiological information 
to tell us whether there has been a functional consequence of left ventricular 
impairment i.e. a reduction in exercise tolerance. Taking all of these data it is 
clear that the cut -off point for a biologically abnormally low LVEF is more like 
30% than 35 %. Although, it is acknowledged earlier that the lower limit of 
normal could be considered to lie in the range 30 -35 %. 
It should be stressed that quantitative imaging of the heart by any modality 
leads to variation in the result obtained between observers, and within 
observers (Baur et al. 1996). It has become increasingly apparent (and this 
study lends added weight to this point) that values of the left ventricular 
ejection fraction below which left ventricular systolic dysfunction is diagnosed 
should be interpreted in the light of the normal range for the centre (Ray et al. 
1995). This will vary with the echocardiographic equipment used to acquire 
the images, the operator, the analyser and the software package and 
geometric formulae which are used for the particular calculation chosen. This 
study strove to produce optimal conditions for the derivation of ejection 
fraction in this population. It is accepted that this value is not applicable to 
other centres. It is, however, abnormal for this population using this method. 
It is also worth pointing out that the cut -off point for abnormal used 
in this 
study is not dissimilar from that in the largest clinical trial in heart 
failure and 
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asymptomatic left ventricular systolic dysfunction (SOLVD) i.e. 35% (The 
SOLVD Investigators, 1991, The SOLVD Investigators, 1992). This is 
important as a) the method used in this work for measuring LVEF gives 
similar values to radionuclide ventriculography (Stamm et al. 1992) (the most 
common method used in SOLVD) and b) 21% of patients were randomised 
into SOLVD on the basis of an echocardiographic LVEF of <_35% (The 
SOLVD Investigators, 1991); in SOLVD, RNVG or echocardiography were 
equally predictive of outcome. Indeed, in SOLVD, the major benefit of 
enalapril was in patients with a LVEF <30 %. Those in the range 30 -35% 
obtained little, if any benefit (The SOLVD Investigators, 1992). Having given 
some consideration to the "gold standard" used to detect left ventricular 
systolic dysfunction, it is now possible to outline the significance of the 
abnormalities detected. 
The results presented in Chapter Three established that left ventricular 
systolic dysfunction is common. Moreover, they uncovered the fact that, at 
least half of that dysfunction is asymptomatic. The findings presented in 
Chapter Four confirmed the generally held view that the major aetiological 
correlate of left ventricular systolic dysfunction in the 1990s is ischaemic heart 
disease. This chapter also drew attention to the association of hypertension 
with left ventricular systolic dysfunction, especially in the presence of 
ischaemic heart disease. It also began to answer the question of the 
importance of the asymptomatic left ventricular systolic dysfunction 
which had 
been discovered, in that the majority of these subjects had 
prevalent 
ischaemic heart disease or hypertension, suggesting that they 
have disease 
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similar to the patients in the SOLVD Prevention Trial who derived benefit from 
ACE inhibition (The SOLVD Investigators, 1992). The work outlined in 
Chapter Five added to the hypothesis that the left ventricular systolic 
dysfunction identified was biologically important in that it caused a significant 
impairment of effort capacity. Chapter Six extended this finding to confirm 
that both the symptomatic and asymptomatic left ventricular systolic 
dysfunction identified was associated with a compensatory physiological 
response i.e. raised circulating concentrations of the natriuretic peptide 
hormones. In addition the natriuretic peptides, particularly BNP, were shown, 
for the first time, to have acceptable accuracy to be used in the detection of 
both symptomatic and asymptomatic left ventricular systolic dysfunction in the 
general population. The results detailed in Chapter Seven, whilst confirming 
an association of the ACE I/D polymorphism with IHD, provided a novel 
finding of the DD genotype seeming to confer a more favourable ejection 
fraction especially in those groups, shown earlier to be at high risk of left 
ventricular systolic dysfunction, leading to the mechanistic speculation that 
the DD genotype may allow more advantageous remodelling post myocardial 
infarction. 
All of these findings have implications for future research and clinical practice. 
Several studies require to be carried out as a result of this work. Firstly, 
rescreening of the population by similar methods to establish the incidence 
of 
left ventricular systolic dysfunction and to answer the crucial question 
of 
whether the asymptomatic left ventricular systolic dysfunction identified 
does 
indeed progress to symptomatic left ventricular systolic dysfunction. 
This 
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study is now underway in the MRC CRI in Heart Failure (University of 
Glasgow). It will also, provide information on the predictive role of the 
natriuretic peptides in determining prognosis. Further work is also needed to 
test the usefulness of BNP in detecting LV systolic dysfunction by testing its 
use in the high risk groups identified in this study i.e. breathless subjects and 
those with IHD and hypertension, to ascertain its cost -effectiveness. From 
the more mechanistic genetic findings, it would be valuable to test the 
hypothesis further by utilising a treatment with an emerging role in CHF i.e. 
exercise prescription. It may be that subjects with CHF who are also DD may 
benefit from exercise training. 
This research also has important bearings on clinical practice. We are all too 
well aware that the syndrome of CHF is an important medical problem. By 
the time it is diagnosed on clinical grounds, as well as being associated with 
much morbidity, it has a mortality which exceeds that of many common 
cancers (Swedberg et al. 1987,The SOLVD Investigators, 1991). This 
research has highlighted that symptomatic left ventricular systolic dysfunction 
is common. Moreover, it has ascertained that its asymptomatic precursor, is 
just as common. The left ventricular systolic dysfunction identified was 
underdiagnosed and undertreated. It also existed in certain well defined 
clinical groups. BNP was also shown to have acceptable sensitivity and 
specificity to detect the systolic dysfunction. As a result of the information 
which has accrued over the last decade that ACE inhibitors reduce 
both 
morbidity and mortality in CHF and asymptomatic left ventricular 
systolic 
dysfunction i.e. there is effective treatment currently available 
(and with 
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several other therapeutic options, including beta blockers and angiotensin II 
type 1 receptor antagonists looking promising). These four points fulfil the 
first of the five principles required for screening for a disease (Wilson and 
Junger, 1968, Rose and Barker, 1986). The fifth is that screening should be 
cost -effective. This is more complex to define and depends on a number of 
factors including the cost of the test and the efficacy of the available 
treatment. Currently a BNP assay costs a fraction of that of an 
echocardiogram. Rapid, more user -friendly and cheaper assays are nearly 
available. In terms of other cardiovascular therapies, ACE inhibitors are very 
cost effective treatments for heart failure (McMurray and Davie, 1996), 
principally due to their effect in reducing hospitalisation. Formal analysis of 
the SAVE study also showed them to be cost effective as treatments for post 
MI asymptomatic LV dysfunction (Tsevat et al. 1995). These reasons 
suggest that any screening programme for left ventricular systolic dysfunction 
is likely to be cost effective. The ability to identify high risk subgroups is also 
an important consideration in terms of the overall cost. It is worth 
emphasising that the antecedents of left ventricular systolic dysfunction lie in 
easily identified high risk subgroups (hypertensives, post infarct subjects, 
those with angina and diabetics and the elderly). By comparison, 160 women 
aged 45 -64 years would have to be screened by mammography to detect one 
single true breast carcinoma and as many as 40,000 cervical smears 
and 200 




A programme to detect and treat symptomatic left ventricular systolic 
dysfunction and to screen for and treat asymptomatic left ventricular systolic 
dysfunction does seem to fulfil all five principles of screening. This work has 
placed the question of screening for asymptomatic, and detection of 
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